var title_f2_30_2528="Taenia scolices";
var content_f2_30_2528=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Taenia scolices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Scolex of",
"    <em>",
"     T. saginata",
"    </em>",
"    . Note the four large suckers and lack of rostellum and rostellar hooks.",
"    <br>",
"     (B) Scolex of",
"     <em>",
"      T. solium",
"     </em>",
"     . Note the four large suckers and rostellum containing two rows of hooks.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Taeniasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Taeniasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Taeniasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2528=[""].join("\n");
var outline_f2_30_2528=null;
var title_f2_30_2529="Stool sample 6";
var content_f2_30_2529=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADuAWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqo2V1ZZoiqt6f0qpqOlrfwRybvK8teq4/I1oeW0rCMIdrd+1S3ECmMx5ZVC4I9a/K7tPQ+jMOy0iBMOJmjC/xda24LaS2STY4kZhkbx2piGG3EUP2cvE2Bk9R71d+0JFI24Ou04XIwCKTTe5fNchn82VkUYChOQvqams7V4JXkmkLJIu0hapNfOl586Hy+eOM/TFXtNv7eeEmGcbSMEuOQajlbC6RFfusaYVir7TgHg8ViXclyYx5zMwBA3jjI/Cruo3Ze9EbQvKQn3kGc+wpl6j29kqiJmT1K42n3qkrBe/Q19HX7LC87yB0K7QWOefU1U16zjmHyPiZWx5YbGM1Ss9R+xoFmPmZHIXkYP1p8Gox3t7hY3YR8jd69+n0pKLtdDbV7MrzaG6i3k3t55ccN82V71B4ytxbzw3DyOcr/GxGK6i2kM6maWBosAsNx6d6yfETaNqMSRXF/DHMT03c+/WrhzOXcV0t9Dz+e6VoXMUjGNurEZK980/T5xdRxxTzJLsTccqcA57j+Vaes+HJNPsJHsM3UcnzLt6n6VzJmu7aRDPAdLgTrK/Jb2IxzXZBRqx9z/g/5mrk4mldyppscU0e10l3F3I+YnsPyra8IaT/AGrJBfalGYra2cmHcv3mxw34e1RHw0+q6Wlwjxz2pAJlRsDHp1rvrWa30nQIN0AMUaDCZBJ96wqVFy8sfiJk+rKUekLaytdWkkkiz/KVwDg+tWzGLMo0mWlwQcDGAauabfwX1ot7bKoTpsz0FNvmjV557jyyiJn5mAx15rCSkZJohgZhbzvIzsW+6prI1W1upvIa2RwoX7y9SfSprW8EqW75LRO3AD/dwehrSjSG7uo3BMSQAlUA7mhXjuGjehQtseXHNeTeV5eAEBxk/Ssee9inlcRtJuL4bcOq5rXmskmliExdUXLFfuk0zUNEjmjjlGbYRtkEdx701a4+l2CtuhiwNuQUBY+/FF1ZCa7g82LzIkQnd6+xFZMdw0GofYGbzwzbw2cnH0ro7VH8tfNtykmSnzdF980NcupN9Sjc2hcQXDQoqxjKbsHYfaq1nDDFOtyiySStnIYcLWtJtkjEUsigElWwMjg461RQpaZih3yxZ5YHn2pajui/auYVaO4YSKOVP17U26nWPAVUY8Y45zWXqWpNa2h8tY9xPzOx5Q/Sq9vcS3R84TeXEOSCvf60+Tqxc3Y0L1FkQSXGVeTHyxr7cVmTxTx3CQ4JQJvO44O3+tbbxq9hFJPucBskDOfY/SkdYN7HchfA8tefm4GTjrQtw6GFagMr5TC7sAsB3p9vpUm67Z9y7+hwBgelXplJERk3FQ/AVRj2zRDdyTyzwuio6nHJ6r61V30FZWMmG2uIZxKcLaHII3YBP0q6Lzawt5yqkDKkdSOua1Ztktr5c0cSqozwPSsL7ChvhcTsEZwVRcbhj8aa31FJp6mnaMWIScgo43b8cfSpDcrG5M3KY2qp6e1QbT5b25mZnY5VeBxWXeO9pcQR3ZJj3AhhzjFCQrXNmVjdbxyF4JZTjHtVW6SNTE2FYjIx6DPrVqCSMuI1ZGjxu54zUcjW5aSBoJGZ8iM9l96Nd7CVhrD5fIEYQMPkOf1ppjAHlPKcoOSP7tLHEskBWferwrhcnj61DePbLCY5QpbIOSp5P1pN6jS0RcW5ibYkRDx4DFcfw1TmlVnZLOIBhkEFcY+tRyJfSRwbV2Q53NjioLpjMk5ZhHltoXozfjT0YWaJ7aLysmbEko+YsOwrC1/VVtXlljSRpFHTPFdJpsXlwBC4cjgseprM1jSTeKiMwXbznb1q4tKSvsEWne5k6deyXsQlnlEQ7qDkg0VpaXoltbyyFH8xjywP8NFXKavpsRZepsRzm1ikyzOQuV5J5q/bXMslkDcRqJsfMo/p71W8mQyKrQ4Kkkc5yKcdy3CM0nJP3RXPc2ewSxiW43IXVkGGJUdKWE3EqZkCsq8g+4pHmuJJ3GVWJMAc8+9WYDIp2KARnJJHak9EOJUiS4KTSTrHkncSw5A9qrQxJ5YWFURHbLDpn6Veu1AaeRX2S4IRQMhjjv6VjtfwJ5TXMLO0eeq4Cn2ppNrQOpffyZrpbWMZ2jO7OBxzjNbMqm5tYlDjYqgOh5xx0zXN2d1Fey+asaqrfMCDyD+NbtrIBavuPyhh82MYJ6VLTTsO6EvLSOXyQfJw/EaggE8c1nadFHAkkyiPdHlii87h715f8Z/EUkF3FYWTqwg/fPJERuViMYJHbHNc54a8UpB4ZvTPdPDeyODFBEoCsOOfQd69GGVVZUVVT36EKvGUuXseh678S7ZXuLSO0nt0AKK5HBNeVjUZ9Wu3Ejt5zElTg9P6Vrabpj+K9RFvHeRkgBz83BPoR611mjeG7Pw7BeTNJbyTRt5byzgbcnjjkHI+ldylh8FFxS9/TQTpyqNdjS8NQXUPhg3E2vMpXAjMbcRt23ZH6VnnVLjxRdrYeJUgEGdv22MDyXwfUdD615R4l1uUyMkNwrESE74uBx04/rVrw5bCXTHfUZmEEmfJEcoyW9CvOPyrR5a4xdactW9NNV6bExrpy5Irb7j33TNd0a0uh4fTYElUG2NuS24Y535xgk5/StmDF0RGWQWqLtKkZI5rgPCYXTntZv7JguLkL5URIJkQdiT06V38M5ivIvt6OolwBsH3frXhVYqMrR1/XzN5Im/0fTbBvs5yrMRkDgAe1VdNuo9WhuI5o8EqBz0b2/8ArVBr0tppVjJMSMu+1gDkL7471wuoeIfJs8bvInjPmRzw5KSr1HHXqKKdKVT4SdDuYonjnuFkUMy42KBtUf8A6q2oY4EiOSd0gAfHJz9K5bwb4zs/EF1LFeW6R3YRTvRc/MOv09a65AVm8yKNJAR8+R0+lKUJwlyzVmS2ug+UqUjMJ3SEfISOfpSTL5kJ81SQuMLn881LIIrRVJdm3c5UZOPSqCzpLc3SkSBYwCQCecZ7VNuoXvoZNvYzw6lcyqYWyB5een0710cABTZvI7lQelUZEhnSOfEgEfTAI/Oqkt9HbyTujYuHTDR7sgDs1LfQfmy/eOyrMu1hs46dRWdpUrSrJcNb+Uz/ALs7uA3vVi3lW6010FwzStxv9Cf8KrLFImnSWd9IUlgO7zEGcjtTsluTvsVdS0f7TeSpMXEO0E46fh61X0aGWOWaxlRljGevcV0DhZ4bZWkOVUOXT+IYrLlmSXUCZUdJFJRPm+VvrU3k0WmloaEV2/2Z4ypURHA77lpjo77SyRLNsPlt/s+mawbq6uljlt1gcMzYVvb1Fa+n23/EuCDzGkUkjcc54qmrakDrl3WNi6p5rkAKOFzioxEvlR+ftWdlJcjOafc2vmGO5Ql5QAQpHHA/xq6CwEkoUq4xv3EH8hSQPbQrsNyNbrvUEff6jGOv1qnNlYlMAMksI2AEdPfFWbqJXVmeQhsYPBpLe5R41kiGFHyuSKYttUJaSpNCGuYgsg43HjJrM1fyliMUyAkAupU5wD0/Gpbyy+zbZgC8fJdWPJJ9KhtIULtMkgdmX5Y2PNUtAfcpQ+ZFDsimVZGYBGOScV0EchU7XwSBnOe9V5UDQoIolW4YjcB0x7GrI+42/aXJ7DinJ3I13GXEpS1xcKvmucJjt9az4mjnMlnOpEkLbix/i+laCwod7zjfL1X1HpUzFJAokVAcfMSeSah6lp2HJMs0a5JSOMbVDe1V54Y8RyFY5QSDjuKp3cyx3So6OsaKWyOgHqaS2mY+b9pljQKcrxjApruK1th8i/Z7syeaQh4EeKfJcRrGbhzkEYIFRRRwyA3QJk38E9sewqxHYROzTYICfwlv6U7dGK63KKRTvGBaOF5yTJ3oq9d2gmXe0jLjpsGBRQpWKtfUtWcx+0smRkjgj0+tOumaDdIBuds9RkVlQXcq3DBuAowV6cVDPfrfs9vC6iUAjO7oaSjfcp6aIsafePJclbkokRJ2845rTuCzR7onL7TkdvzrkdO0q5tJ2e/Hy5zuLZ5rsEMO/wAtcRjg5zndn/OKU0k/d1KS7knlrK+0BlMgBIx1P1rN1yzntXgUgvGeMAcH3NbFnCkcgSI7Qvqc/jVTWtRVJyjOAFG1WPeohduyHJpK5ztoFbUZIidqAk7zwFArYu72OKzlDSQqQnDBw23jjIHtzWDoFxHLZ3JulIZnPCNgkZ9ayfENndSTxzwqLcW2SY5CCFXrlSOcj+Vbcic+Vuw4pyPD/ET3f2u7iu5ZDI0u53IwCe1YEbuHKjdtXlsccV6N4nur2VptJ8t57V3EseVyyv7d8deK8+ltZI5DGI33jhh05z3r7vBVeenqkjy69Lkempo6Xrd9p9w8ml3U0MmOCB972NJq/iDUtSO+/llkmXqWboK6HSvBl/e+HhfQReU4UsEIOZPcVjnwvrZkUjTbuRZDt3FCefTNRGthZVHLS606XCcKqit9TCi3yTbA33iDz3rpFNxHFELHLOi7H8sZBOc/1q/beBtQkMUcltIbyR9sMO8YA75/wr0nTNIn0KdtLa1tYJXRG3Lg7TjnPvXLjcypRsoNSfY1o4eaTctPM7XwdDJo2ixQ3cIbUvJDM6HfgY9/x4rW8SamsGnR3k7eXAitulGAU+XIyPc1nWY/fJHbzGWaZQpJwAg7kD161leOXmk0W8trURXE0EuHhLgLKowcnvXyFNe0qe913O6d+h5Emtvf3j3utWd1dW8shY7nK7jzzxxxmvQfh14ZfVtLuru+tTHaSSZhhJO5F68Z5x0/WuBe6uPDuopZSxpdMkpkWFJGbyi3qcYOB2r2nwN4ij1nSUE0CWQEjJIUX0APHqOa9jMZSjTTpq0X1v8Akv1MoNLTqvL9Te07RNH01Wns4FgkZcbiPvN61oW8YBkkSQLM+AC3K/Wi2uY50kRNjOvbHzDJ4OO2addAW0YKDLKQMBSfzrxNb3ZTd0ZOr3czRQJbMAQcs0YyuP8ACotMjvYppJ5rlJVY87eDt9K0LWJ7q7dDIMlCCFHGDzTrqFYIACCuSBuU85qm3awrITUJfPslEzCGP68msUJbGRrgwN9mkXDbh6Vd1cIFZ9RclI03KvfPvWZpl9NfxrsURp0KnnNK3UfQ3dIt7cWsgUbYi2QR3qPUrsQylLdcbn2Fic7h2GKdFG/mRszbUAw6rzx64rA1H7W+qSJZKiiJcgMOSPWlvqOKu7Gml3A9oUtwFkVjlicY9RVSyEM8kkU8LFd2VqO10q6uZbe7SMxKPvEjAOe9dDPpjQW/mW2DOMAjHFDa6Ao2Mu90+Fo0AkCeU2c7uVHpV+0VYljjgJYZGVBrKuiyk2lzE5GS7uFxnPv61JaXSbYYo2CWqjazMfmzj1qiPUvnJ8x7cIxBO3a3QD1qq8hmQGR/LkBy4A6+1LLKpaOcLtkYlAR1wPWs62uLadbqI3HlyRqxwRzknrnvRqCW5oPfxSzkxNwuMg+/AzWes5hIjuD5s/mHakf8I9DWakPnRR3O8Aq+11559KvNZeXN5sKE3Lr8w9PpVaBZrRkerT3MFuZpVViGIKg5OPpWesk0htnCtaQcMzsPvj0ro9KhtGEkiL+84EgkOefWsbWruC2uMXjqI4n3IMdW9KabbskOKS0NEE/IkUygqNxkxxiphOpVDEpw2cEnqR3rG0+5N5GXZCiAEjHG70qYzyw2vnwQF5D/AAegoaadiLF1hInzB90xOWJ6D2FaEMclxFvm8oPn+E8ke9ZkNwfscUl1mMswOwDn6e1WjLbpN5sQkEoP3OpaoaGiGa3Cu0rTuZQMEDkClWCKWAR38HmM/Q9Mj3qF766lhklS1CSk8Ie9WrQtIsTTf63oc9FNCVuo2+pWn86FR5DKsCjAVhwMfWm217JezBY0Kgdie9F/dq115EkisoOcqOMVDYJA10PsiDjkknn61SQna3maStJAWN1khuVAorG1OSSO5zJN+5XqcZOaKaV0HLJ7IsvFHqVy5inMIj4dTxu+tO0nShHdObUAjGMsMkU37THbXPlpE5xwcrnP41qWN/CqzCOPBUfMfSok5W02NIpLckuLa3MEFvI/74fMWLDL/WjT03IkcgCbSfmbv7ZqaN4pUiPBwMBm4OKPs222ZbdQHIJVickH6VDdxpWK97qqRgAqoRcpuzXFa1fvd3C21qm9D8+7OcfStPX4Lq8VIYmCyp9/I4PvUen6dPbQK2EcA4G31+tb03GCv1E1fVlPw0Y/tEcbglixU+u739sV1rafBfSvPK6AINvkmsdbOSO5jQGITuNwCryKs3639rZ/a5Y5NqH7wXH5+oqJyU5XT3KV18jH1LwVDNfedaakLaZs43puCntg15Dr2i61p93cy63boHVt3mYyr54ABHHvXY6/44uVuZQZ0aNcfO3yj6VjavqM2v2F1cRLtARMjdgHbjOAe9e3gliKLTnbldv6uZtKexW8KeJr23nAbE2cLGD2P8q9m8IX12+lH7fDIJCzAggHJyTxjtgivmOwu5LaX9yyrubjPUEdK9h8NeP5YtNitp7yxWR1zvYgbjjoQOlVm2BlpKlFDoTU1ZvU9Hu9DimlikgVUkXEiTJkMD6/SoptINxcPfXhW4nx8xAwQMYBIrgH8fSq4+0axafZlwo8vB5PUYxkYrO1D4g5nna11VCq/KP3eSeOTnpjIrzI4HESdkvz/wAjRpJfEvvX+Zu3+ibWSaK7iULJ80Tjy5CCc8N/k1REF81vd3FlJCWjdvlZtxC9GAyMnIGcZ5rgPEHiOTU7h/tOrF5Dj5Y4tyg9cg5/Wp5vEV3c6QIYJ4N6/M7LJtZgOo57/SvTjgKyjFyd/l/w1zJzWqX5noM3g77dqL3nmG9uLrA2RsFEPTkHrnjqa7zTvDkWjaY9tawxxyRckgDc+eucV8+aDqevWkiXFtcSxRMMocA5575r1TRfFF7d2oTULuNb0nk9Cy+1ceNw1emknNSS/rYdP39otHpdhl4S8MSpJIQSVHJx60zWpWWLy4k3znOQ0mwHNYvhbWbRzKt3eRMT8yIWAP1AzVP4gavBPo6xadMHuGfYDx8pPQk1wQhJy5RS0ZoaHqRn+0wrmIq4UhSCuO/PrxXRtON6LGA6RqAeO9eM+HvM0qQWl3DdLcxGQyTR4Ic44PJGQPeu+s9ViuNEilglUuuYpkBG8k42kj09cVVWmoy01Q7SSuzXnsFvSJHRpCflwTwfpVHSdHlsrhy8jYUk7QMAD0rZtDbrAPLfhflGG7024VprlDMu1ioZRuxkj1HesGxpiXB8mAsAjSRoXYycFx/dHqa5RnMGqvJ5TR2srAI4JGF9BXYywOLT9+vmPINyIFPWuHvbqZbhorgMiq2AAOhqoq+jEm1qjpLfU5ZJWsJG+zqV3K+OPamS6xfaSFF5H51uCMSJ/EBWNLj7K7ozOrqAeDvB9fpUdnqTtI+nIiyFuvPAA7Vaj1RF2dlYavpesFU8xY5HG4I/BrIv9AeQs9iycMSB/wDWrJ8Qw29pJbTJG0ImGAFBYqe/0re0WfdbRuPuqvOTztPeodt1oaWe25x+q6ne6TAkc43KRgsR932qtFf29yiMbUIzL87A9K63VreGRWUxB9+WWRhx+NYFr4fFzcsWIfzRtWMfdH19q1jUi17y1JcVunYZqWrun2dIUijhyCc9yKteHtSa8upXuGKtkKPp9ah1HwlP9kY7zJOrYK9OO1VNHtLjT5CjNguwUhu3/wBeq9xx0Ja01Oqu3eOBhDbfM+ASOo96zLjS83Vu10qyZPGecfWr1sSspt1cunO7/Z+tTTXCxwrIjBowcEdxWWwk7bFRrBTKZ1QKcYC9hViJWR9106LwCAB1qWJonuJHMnAXO09uKZb2weMyTqpkDZTn7wpDv0YzyEZklWV8xvkg4wfbmka3V71nkmImJwoxgY+laFxO0yqZIwpHCjHAFUwFluTKwDkDhupB70nca8yvHHaMZrkSlpIjtYKelTyXlulqhjwWcnbn+lVAFWUpBEwR2JeU4wTUgWORXcqQV4BccD6U/UHocX4qnma/IVzGg6npmsTT9XvYL0Qq2cnOO5FdPq9jFeTsCWKqvBUcsa5Xw9p142oSXKEAJ8uXXJr0MO4Om79C6ijynaPI88TLJG0ucEAN0oq7HCLS2UzOMtySeBmiuLmtsQm0a1vayQFvIQMGf5mk7UWthcpcXEk6orO5MYUcle2fenQC7vBbTRXbW0KhhJbFAfMJ5B3ZyPpWTrWp3FncpHamZt5+9nhazinN2TLfu6NHRIJS8iOxkiDAoAMH6Gk1eVIZIY13BEHLA8g0eHtZjvUxMUWUcHAwWpms6fBCJtiMXl7hsnFQ9HqNFbUwJpkWGTcu0HIB4+tZKG5t2mjumCxo25CBjNNsrWSG8hEV4zDPzRls7h6V1r2tteW3+koQDghSOBjik2oaGlubU5Kx1VI9bW6khkfC7VcdK6PxF4106TQngR0WVkKENxg4rPura2BHlHylTlRjrXlnxP0+JE8+KRgWz0ydxrqwkIVqqhtczqJqKe55/wCIblnuHu1RTb7jscjgt06Vz1xqk/llRIc92HfinyyN5E1uQ3Hz4J44rIY5KknivvcPQio2fQ82rVfQc0jzOASdx6CnFTF8hB3A5K9BSBDjcB+NRPnfxnNdaV9jB+6rseGIPBP0NOLkbMY564PWq5Y55/GkJzT5TP2ltiyC5GBkKOhzTPMIxuPT0FRbjjBJpppqIpVOxdgvJom3RSyLng4Y1Zh1WeLG6ViMYxuPrmsnJ9aCSal0oy3QKs47HbW/i+IWbQtaQhmPLMoJwTnr271JZeJlhjci4Z5NqhQwPBByPm9veuGzxilDDHNcrwFF3stzoWOqdWez+G9bs7rW1vNXumKSPsd85PzA5Gc9K6iyj0vVPHay2ctw0UbeXCFi8sEAcknv+FfPNndyWz7omw3qRXZ+H/GFxDPEpupbVEX/AJZ5ZCQO6n+leRjMpkrypPpY7qOLp1NJ6H1RADYCU+U3kwqcrnv6Y/z1o0+NLra9xIxuLkHy16BfavIdO+IgntvKv5sRuQN5YnH9R9DmvU/DV9pt3bpLBPG844RWcc+4xXy1bD1KOk0dHL1R0j26SxC3lkICjHynjNZ93pS3UO15iHDggqu7P5VY1KfZ5PyszTPtKIOgx3qle6xbWVqivCWiU/NkYwfesVqxbFjy3hO1QslukeRI+Bmuf0mxhsNbl1AmIxyneWU9eT0qvb+NoC2dsKo3ymM9TWk8kF9BFFGyO7nKJEMBMdelXyyj8XUltdC5rF0Et2mltVmtzICpKZ4PUe1QxeWkp2qpRx8sanoKtOqNvh87zJki+ZMZAPY4qCS2jndJIIzEuMsy9+O9Q0h3ZnbhI9x+7keaNgxjc8Aen5VrTQwOscsaLC7KFKoMYrOt7NLW6aeEsXdejHqfWs6fVG3STTQSRyxHaEzhTz1p8vRBe+rOjlkfJnTeCpx9O2f0rmL+VIYpmvHDzM+5COoresruKexEs4KjPKkY/Wuc8QLFPcPIfMjjQgqVHD59KqmtbMmQ603MEht5k2lvnJ4zWnZW7qWRJlkVpN/7w5246CsXw+UiWVZmLEtkFutbsMqIryiYPFjmJgMEev8AOrnoyVrox+oRRSvI6SxrNj5gBxiqywxqiXEUryOgyCD+YqKW9MtsJIY4zGSEGTwoFWYlihVBCgb5SAD05qR6kazG+Vy6FCD1LdKsDekSmJkG44IIrMmcX5ZLWbyJomywxjH19e9Xoo5nkjMqLII/vg5596Gg2GGzS7ueJRsQktg1DfWwuoXgEpCZ+UirC30Lzy2TwhT+RI+lRXkkqzqkNoVgQgEqv60tVYaIksRGIo5pgy7QoGMZP1q3PaQRBkhPlMBzjjFPS4SKIloTOvUHHQ5rF8RXd1HbmQr5KnqqjOR659aau3YGr6jtWtob5VDmWQJwSnQUVDpQuEsFbLyZx1GCRRV6x0TEpXR12nCDzEhRWxknJHBpdW0ZEuEmhAP94E8D6UttcEjaPJjcZ+63UetaGnT7JCdxkRh0PauRtx2N7X3PNdThm0XUDcRr+7lbkj+H6111nMupwQyox3jj6VLqOnRyyTb3yZF+UH7orK062bTZXSCJ3hI6d/pW0pKcddxJNaI0ri1WNBJFCGmztk2+lZ+tXbWunuGTYxU8lvbiteEQy2zq2+JgMsGOD+dcz4v1C0OlPGAs0oXr1J/Gopx5ppDk9DzXRtWvL3WFFxOxZCR1+XFReOryWcfxbNx6dKyNI1Fba6lK7RM+QFJ6VX8Q60WheNRnGQRnv619LHDP6wpRiY86UNWctqSrNcBo0/d4wx96wbi3e3d43wCOR7ir1xdEjauQPTPFRtIQg80F5F+6G5+WvpKSlBWPPm4zZRLFV6dajJO4mpJU+ckjHfmoSeTiupHLNtbiHrSUtJVGIUUtOA4yRxQNK4yinlcDPUUoUYzkClcai2MpKkcDtwaRlIxzmi4OLQIQGG7pUqlkYGMg5Oai5U8UHIAxkUmrlxlZGlbahLAr4RWyNp3DINb2j+LbyzWIWs32doz91RhT6E+/XmuTjyR97H4085O3epB/vetc9XD06mkkdMKs4q8WfQ/w++KDT3ATXMzyyYWNgRnp+RNb/jtpJ9JSW1dt0xDMc859x2r5k02+ksriOQYdVYNtJ+8BXo2h+IHbTo3W8aZjISIiRujX0APXvxXzWOyn2VRVaW3Y9HD1o1Y8stzR0iyuZNVWJydpU5yPau60CabSJPtiyLLEWxtY8qR1pfCF3ZMoNvLCbl8kmQdfYe/tXUadYspnubu0TZu/dbgMHNePicRKcmmrWNnTUNHrcbqPiVdlu9oqG4lIEkiLkYra0q5W+tBKlykMjP5Ywfvf/Xrmr3QAyJiURFnBaPp36A1p2+mPa222VIsRtuCrwDnqcdjXLeEloRKLizpIoIHUo06Bk+UMcc+4rP1C2spX4n3OrAyOSBk1kPbSogWAYR2w4J4A9qp3cURZN3yqwK7xxg0cqIu2dFO1jEzNczLNDjmM4xjpisi7njeORbaMfZyP3Q2/c/Gs6Cw3RsodnQHMnmDBP4mrsMAZArK0YA+XB5Yexp2indBeWxz8cUrXca7k3y8/KeCBXUxhUidmZFTbtCEg4NQ+VD+7eKAfL/s881bEkQid/LBkUYICjoKc3zbDT7lY20sunxiNol77Rxu47VHIzCVJJF6qAzDgL+FTR6kssuxQFVefLGNy/wCFXJlNzcBUQi2HJf8AvGpe4LsVbcWgln2xSFiPvsvUY5rQ02zeS1kmWQlWP3NuCB2ArPWaEXhihYkNzkt8oHoK1bS6t7Z28+UFMgYWkx2Oc1u1eCaC4lJDseDjv2ya39HnW6iSVjkSqFwPajVbdLyOVVJEMgyu4Z/H2rnfCTy2l/PZT4UsxKFscAdxVRV00Eu50xtkty6bSwJH7wDkD+WKztVgS4tmMsgcdMA9K0Lq4AtZoS+4kfKydRWTiKWwSAqy54Y9zStqK+hFFujZIwhwF6mipbhoo3jxIw28YboaKajzakt8ug6aSZ282BElB+6SBwavWEl0q7WgKyAAkoeDn0FLbWVuUZBPmIngCpbO0hCA+bKrDorMCRj3FZPU3IGv2hlMEaOCBvfcM/gM0+LF04Dxy4dfvZ+Uc+lNvkVp1bdnHyt6D3qayRkSSOJ3HbJPP5elJ+Q15mB4puri10mcgqsi5AbPWvFJb/Vrm6kiYSeXICCQMkCvoTxJaW9xZeVNKrOfukjofeuAsIbKxvJFKI1wjHOea7cJiI0YP3bsHBSd2zxvWtDvbACVyGPXINc3cXMjMVYnNezeP9Wslt3jIjZyOOOleNakvmSNIg4Jr6vLMROvDmqRscGKpKm/dZUZVHIPNJDcbJkZxnb39qvaZpNxfAtCjMB1xVDULX7NKVYnI45FepGUJScL6nJaUVzDb2QO5ZRgN29KpDPap1LFSO1RrgMT+lbxVlYym+d3YzbzijABqRMF9pHGevpUlzbNHg7lYN0I70+bWzF7NuLlHoQJjPJqUrtVQw460wLtByPm9KTzGAOOKHrsEWor3hXVQfkJI9aao555+lGeB60oAxnNMnRu6HrtHJP4VGRknnjrQRk56A+tAOAR1pDbvoKCQeOc0pA6Ht2oQ4Hqe3tSMxJzjmgaskI2AeM4pwkJGGJ4GBScFQD165oySuCPxoErrYUA7d3ap7eQxMHjOGFQ7Sq/KeopnI60mrlX5Oh2/hDX5YLiOGENu5yo7/T396+gfhtqV9rGnNG8oMStkrMcls9/Y8c18n2crW8yzQsVkQgqR1Br3j4f+IY1FgSs3+rUz/L8qvkAHIHRs4Oe+K+Yz3Brl54Lc9bA1PaLlk9Vsezz2EMb263Cidw5OcEgen0p91AblmjDbcdwef8AOKZLILi18+yH7ojzCzHkrjsPWorYyBXiL4Mb8/KAzHAznHXqK+WXY1fdlC4lk81YldEIJ8xT3A7g1CDGiiIbpNxzhhnA9av6lsgQxnYrXIYKJAN2Af4e+M1h2+pBmS3UmeZcI7KMbR2xVqLZNyzcGBYJZDIJ93DY4I7Yx61NAxWOMK2xEXaCBkg/0omEayvmLy1kG0BjjJ9amsvNkimEqR4XGGDAhxjr7c8UdBAySQoSrOd5DAtgDGOgx24zz61n3l+8cgSGWNsg5UjPWsHxq96IgvzRK3ACkk0vhTz3gjjkCxzJtyWHLj1rRU/c5x9dTo9KtIntBclQ2/8AjTPP4VZn32sXm+Q7zq2Agbt64qW5BB3KcA/MRnH5CmLdrFeKqSgPjO081k3d6Ak7akWqNFHHEhjEbsuV2rwh96dpodrLypSGlPJfbgGtCYCRXlmc5A25Hc1zt/fw2DLHL5jMxyHJzzRbmdh3skdLI5EEbvI6+WBuU9/asy7jV777QEVJAcEFux70llextEwklYGQ5G7+VNdVljUSxjngk8Gi2or9yJwkEUsY3faFOSzHIal3tDEsbnkjd+NLviitwkhGGOFI5496wdV1SCyjRYpRJMxxgmqScnawWutzYnvLZCEmgVuPlGeRRWU8VyYIpOPOPZvpRVqF9bkt8uh0+qXItIpHI/1eckDiuf0+5u7q4+0CR0AcYVB61t3gjuW2MMlSNwwcH1ptrGtskPlKssGd/wC65/WsE7RskbaXuzfQxiMG7UBu5K4yfpQfMUFSiwAqSCMZ571jtdvNKdkRHzADeeD7VevDNJzIxygIAA/mai3QpPueZfEHWpbSKTZJIrHIUsccj0rzOLWtRuGLF33n+LufrXa/F6yvrowuEQRgE8frWH4G0vzpgZkOzHGPXNfQ4X2VPC+1kk2c9pSqcqOS1X7TdMxuC+e5PcVjbQpYNnaema958SeFoTAHiwPlJ+vtXiOt2UkFzMjHoTgY6V6WX42GIXLHSxlXpOPvbnQ+FdRtrOzdHKhsZBGOa43X7oX19JKowCenpVMSPEcE4FRDdIxOetelRwsadR1b7nNUrucVEUKNp20+0jiLAzHjPYZoxhD25xUkJiUjep3DvXS3oZR0ZNc6aPOIR1feMqU6D2NV7W2zEzSfN1CqeAffNdkken3uhqiDy7hCCpPVweormZ7eRJmikKtCpyFzjB+tc1LEOd4vRo650owakle5itujkIbrUdTvGfMIGWA6etRPGyfeUg+hFd6aPNmn8hMcHikHXmnDJ5AzQQR1U0ybdRPbtTkB6jjPSkI9OlOQLxu5HsaGVFXYqBgWVRlvbmmbTuweD3zU8ZRXyRn69qdLHlyAAB2I5FTzam3srxK+Dn1qZF3jaBz6AcmmowRiG5wOKarHeSuR7ih6ijaIuGVsDnNDKT9716ntTgilQ248du9MBPKseKEDVtwjwcgHAr0DwVOyaZdStOy7XQIjMoyRypGe3HP4Vw1lD9pfyY03TOcIK9C0ewnsolhtSGZ4irsRuDFlIAGBwRzxmvOzGUeTke524GD5ubofQXhZ7m/0eGeVGitt2Am05dTyeO3WtOBPLimVYliKudu0g4ye/vVLwvbPaaJbpJKWkjwm1x6cfn0rWOI4ZY4kEbud0jbuM18E7XdtjuqO8mZF5o0V3cQ6nPNLNcQDCwjG3jpzWAdKns9Vint1m/et869l+ldnMEhtD5YAI5b3pGlAUMWDPjIPp7VcZyTM3ZozpbcGcTyMS0CnIHU/hWhbp5qRuECrKMEN1P1pqwO92DIqpKy/MCDT3Xe24AoEchfT0qb30C1inf2ttdTMshKFOmeRkVU0cfLJK8cQcybDkY4zxir4jEylXkH3skAglvamvDE1liNGZepRlwcjpRd9R6FhwklxsnVTFtyOME1hPFFY3i3NwmQWCRLjPFX5JpZbbKymH5cAMucn0NWov+Wcd2kbyp3C8UrdwTa2KywSQ2csrP55lJbZjp6Yrj7u2bUmRWM0cm7DRdgfbNdtebCFcMpwcbV6iqFuhkt5pQNrOMMCuC359KcXyu6HczoFSGFPtCNK0QyGbj8KtTzSSESSlVQjCDPU/wBabqoEUwmk8tIscgJnNWrOGP7P5lx86Y3LuUdKG29QSS3OZlmklaRYi+0DAGcDPuKzo7TZah7i22XBl+WRhyPeusfTIS0kjoyO+MKOAfeibyYkEboDgdc7gPxrSNS2wN/ZJ/KfYrzTKRgYUCiqwnZLRZowJVB24f8AwoqHe5MY3RpwyJFMsSbBIOWPU/lVg7guRhSeSR3qrGhSUzYikd+Wc/KVFSeYFyqzIC5BHOTWVuxpe5aQTqCZIIzzktjkj1q+xZcIrKxYDO4dKpzKPLRXY7iONp6/hVoeaHzFu4wDjkfWkPzMW/0i2vkeCQsWU5JPGPpVK08PxWrnyIjJuyEKnBz610Oo7bdZLh1MhI+YKcH8KfbyBY45kDlGUAA9Qcc0+aSjYdle5m6rbx/2U0bRfvMYHOa+a/iCEi1qSNOCp5+tfSeuCSfTnltt8bj7x3c5z6fSvCfF/hiR5WnLO8jktnbnv0zXq5NONKrebMsRecbI8rum3ScZAxUSk9B3rU1bTpLWUowOR1rPSIlsYJr7aE4yjdHkSi4uzJRCcgqpYgZI7CprS2SdyJnCEDP1odQFUrx2JFPEkcdsVO1jzyRz+dQ5NrQ0ilfUe0UkcOUB2ZyG71s+FpoJPMS6A3lcK5GSM+tZdvrMZjEc0UR5GWxzjuKPt0Fq5ETlo2PUGuepCc4uDWp0U5xpyU09CzJaIklwkeJBIPl49+1EVubm1UBvtEqDZKjdVA7qfp/Kp01rbaRx2kMOVGDLsGRk9/Wul+GsAh1MX0twibJV80PypU85x6f41z1qsqNNzkttvM2jaUlGPU88utIaJwsTbicY7ZB70ybSL63JE1u4I4I64r2fxfN4UuriQWk1s0hZiPIJ2p/sjHc4rmG0Qy6c01vdfaVkdSYeGYehLHnilSzSUopzVvVEfVKbu4nmMqFDtYEY7EYNAX5eGAPuK9Fn0V/K8yfw9M6ogRmTcScfxe34VgjSrGWTEvmW6leoQ5Jz6duK7aeOhNbfk/yOeWF5XZNfkcwFweufpT1cBST17YNdRJ4bt3IEN5DsxuZs5xnoMfzzVZ/DoaNGtLoSOzbdpTbj3z0IzVrF0pdSvqtWGy/I56TDYP8AFT4wBESULYPJA/rXTQ+D5nkXfK0qDIdolyAewHrmkOg21vbxGa4ffKSyopyQB0yBS+uUnoncFhqifM1Y5eQdOAufeljt5JWwilj7V2Gl+Eri91O3gs7W7uo5iVVzCQM16Xpfw9OlNvvo9iBAQrRqcNk88nr+Fc2JzWjh1vdhTwbqS1djzLwzpJguoxfiSAv829MF1HHbPGc9a9Y8HeGHGrTag0XlRKM7C/OTn52A6N6enNbOiaBbzO988QYRr8wYb3fHP3j0/AVsWyKZE8osiKCDHyGyehPrXzWNzGeIbS0vuejCMKUbR1sdDa30flNHEFDQLgjOeSPX6VHCd9wDGo8hQWZyeVNZl2JTGkkk7wRhh8oUANgVNp04njDSTIsP8QHG5fpXmWM3fc2UkRoU8uWN0kGQRzmse4ZvNaeNhs3bMqRnHenx3C5ElqyC3iPKsvBHaplSGNNiIPmG7oR1osK5LZakLmGOQzpzlQwPX17VLcTKhSS6YiIEkcZ59qpW9rbxtslVhGpwFIzuJ6mo9Rhd4DBahmKkYBPCj1oe40kWPOg8sSwwKHxuwwxjPrTrCV7qN3aaLyeQGQk4PbI9qryWlxdyxrFMIlACuRzurSsdOitRKtmCkK/fZR1PrRpa4O60JCiSIUVjtQ54XvUHkzokboUZy+eOCRmi5ke9jMdvcGOSN152ZyO4xSmU5P7nbGjYVs5JPepsO5WYSNLIjQnePmMmcinCBZgC8wQKMttzx/jSXVw0U8RSTJkPK9iKSWNY2aVnX5vlCI3Wl6D9Ss6RXCFi5lkPymMLgY+tJDOtvwh4B6SfyFVkuLmRGhFo8EoyQTyCKp3q3SsjRYmZjllYYC/SrS1E+xsXUiTx7n/1TcfKP61kta4jVLdFKYzsHOee9FreM8zJLbMiZxxyDWqRiMsh4/ujjim1bQlOxRRYZYwYpGRl+XyyOKKmnlt2xsUCQDn/AOvRUcz6l2j0RauHgLBMM74II3cGo5beFWt/MGxgQQvXI9OKWKd9uTAMjnOcsamt7gK+6RSEY8MeSrfSlqGheIijVJ5V/eNkAZpwvkV1SRztfgKRjn1qK+f9wGkQb88YGSKgeEzyRvIyqVHzSkYqXsUie8dI4iq5lkJzy3eo9MvZo2jS9TbK3BEbcAexqsbdbhCzyIW3fKVb8qsIhWbEinG3IbGQKAL0yMyzI7YR1zhRyPesaTTbe7sZhGiyeWpzk8k4q3p08sqTLOHTdkj5gcehpkDw28zC2KuWOX54NOziwTueP+MvBk0StNHbFi654OMV5zZ6LO9w0artlzgZr6n1OS1mhAuNoTsuORXDz+Do/t/mQThtx3EhBlSe1ezhM0lTg4TMZ0lKVzzHTPA9xezqknIYZ4PWuW8d6LNoOofZdjKgHfv719KWukrZsHXduGAMDr71znxJ8LWuuQSGVtkqqG3ouSn4d62wmcyVdOr8JNXDqULQ3PmHPNPUMw4rtE+HepzWlxdwENbISEZlK7/pmr+l+DV8kO19bqqrmUkf6tsdM19LPMsOldSuefDB1W9VY4vTSElxKCUIPHvW/auYdMkmgRGuEG/ev3lPA/TNWPEHhyaySO6g/e2zqdrIvGc9Py5rn9Wgu7RImdtonXcFXjHHt3wahThibOL3/Q0alQumtiol9N9oEqsEkU5DKMYPauu8IT3txI6QXDoWONuOJGJ/SuVtdOkMtqsmFWc4BPY5xzXonhzSbrR4ybu3YRt3HVKjH1Kcadla5WDUue7O30rVry0ttjQO3l/uywwAV98de9bdtrOk30amexgdyxBEyD+Z5rnotTJXZZL5saqAUAyfxqvbaf8AbppJ2HkThQBGBgjnqfWvk3TjdykuX0PUnHmOtn8OeEtb228umrFICCrQsYyT6dwax7z4caclzK2myTwLGuzdI5bFW0dY4bFwr7oX/eXCHr6Zrp4XmvbmKVbiP7Oh+dR1Y9uayVetTXuzdvUi0YvZfceXW2g6lp2qyadeEiRkL2d0zlV/3T9at/C21sLXxVeWmqwRvc+XuhZ0B47gZr0fxfYNrWm+SyYliwyOnXjoPpXnupTt/a2k65MYra/gYWtxB93eOcPjrz0rpjiJV4yg/tK2nfp9/wDW45WlDXdfl1+49js4rV3HkyzK4GSqvkf/AFqq65e24iIvFCiQ4Cqc7fc4rP8AD1p5Alka63ifBwBnCn379a1tS++0QSM7ACspXcXzxj2xXmcqiyFK42K2aG3VYNsSAZLY+8ppY42Ro1dFdXXLMpHSssT3Ak/ecjGDzggfSriySRRRqYSCy7CwPOKLAQ6soRAjM4gZvmDdB7g1Ut7eOM/LtcRKVwpx1qxLcSTYgMe4Dklzzj6e1EcbLeMQwIVeD2/KqFfuMtfPkjk+0RwxRo3yhc/OP5cU21N5PcT/AGjHkqPkKnlh9ParEsgEmJVkBHKkHhfx7U4SB49oEnmA5JB7Z9aNw2LC70RWbLJ1Xj5garreRJeNID833WGMdaZNqMU10qRsRJGMEYwD7fWszU4J3m+1Qo/QqUzyT60WElc6OyvYYrNplyED/elxjn0PpRd6j5bmCLcskpyWI4IrE0YyQI0UluN7DcoJBH1FTXtvPJgJI2GQ42nJzRswZpQXMV0skcLvGykhyf4hUDOLdFt7bzHBOSc5ANV9PtmtIDCy+ZIOQ/Q/Q1NOqeY0qMVPTavG6k0kFyRY0eWEPl3PGMcCpZtPBQOUOd3HTA96o3D3Bifh4znPI5Iqjc63DC21RLI/Hy5oV3sO3ct29yssplO9HBKAEdfeqE1y7ymBQJCxO5lPQVJYzfbImjZTEVcldwx/OrTwxxrHGVjyOWdhjNUtBPcotK1talXk/dJyAewqa1unYRTxv/o/RjjIqG+iR0lRQSjDIxxgemKhtomtLUwKf9HbDAZyVH1pq3UTG68uHVreMhpPmz2Ioq1IUuEPmP8AIMYz2opx22GpWJhkSokCFT1JJyM1I5kAMchjbecAgfdqONZVR5VbcoyeT0qwlyURmWNHkfkVkylsW5dywLuYsQMEg/e/OqDXIa4eaQuiqu3YMYz9KeJ0MqxyHLnkr6fSrP2KCICNPuEbsk5qbJFakKzQpGkk0KxKCChB4PvV2eRQgMzbYn4AHORUE1tBLKIniZ0X17fSk8lQ6eaGwo3IvXafemrbibY84KK0MYjjBxkk8ion8oRy5MaSjoVHHHTNSMzXJkCSMoCkHAqjYXdurmEgs5JAxyAaLCuyRI5nSIjY0uM89OfWrMcDIvz7dxPGBnFJDJGuCSx3DkLwM9qWSWOFks40IR8/MD93vmnYLt6EU9uI1jjuUJMrFlKH+dZut3a20afbIoHincIzPJ5e4f3c+tdEnzhgFA2kjzOOQa57xDoVnrC2ouUeZIJWdAWIGTjOR36VUEm/e2DmsYGnaKk8UFqJWjW6lBkDSfKseCdufXjGapXOjNM01jaLbWtgqkyqX3MZMZwDnvjiuwnt7dS8cgwqISpRtrR8cexrj5YFt5pbqDTWu7fUH2u5dZFUp0fPGOR1PocelbU5yet9f1+/e23oaaO551q+qtp8X9kWHnCNzxG3JCkcg56H2rs4fBUes6HpkNxZ/ZWhj/iGX5HOSO9dVDplpY3a38dnA08qYeZ1yxbGCw7KfoK3dOnkt9NV5iTLkqGAzkf1rqq433YukrPe/Vsxs7tPVHFaJ8NtL0XUI9RkaWRom3Rws+Qh+veti5jsNUmmsYkIJJLyAdPbFaOoyNJEksDkzM4Eg3cAeuPSoLG1aznnltQrM3PmH+Vc0606j5qkm30BRUdIrQ5u+8JfZXdrCaQKOSVPzHvyKgjtdRiuU83e8cgChsc+1drqLTzS2bw7/NByzL8oPHcd/rUtqscyP5gXzlyflOaPbya97UpSaWhhQ2tvaoziGSS3f5Zo8du5FaeiNDaSy29uZPKc5RnPVfStCWKVCykxkt97cfWqtvA8Mu6FbZhuAZXPrxxWblcNy/Y3bwXO0lI7ct+6O7dgDsaw/F1jY3N79oWG3fzh5cqjqeeorTUWyzNBcJOJrdN+yNSwxnrTZraEtBeSwb0DEb1OGJP9KiL5ZXHd2sX9PiSC3ggS3A2ooRmf5vxqaUyK7tKNjkYI5YL+VRwXTxoROu2NmyCxyWx2FWriRYod5bazqMhhnGehqfMWuxQNoXMtxPtKnAjIf5l/CqC6orSXMMoKvD0Zs8D1rTlkjitFdWWR14GDxz7VTvIBPGEl+SK4Hzj+JvYVasJ9yndXUtrbwurj5k4cDJJzWLe397Pdm2R/LGM7+1bv2GK1tlijUlc4UZyQBWfqEULWwG8rJjp0pppFR1d2jNtNQkSd7S6drouRnacYrtYOcFmUfIOF5/D2rl9L0yFAJULLKcBi/f6VpxSpbOqkmJUbLNjOfzqpuLehMtXpsaMNmkt1EyhdqEs5brnsCKn1KeCOAKI2JLDoapxX4lQS74zDvK7+5Nc34rW6a1MtkXZg/wB3sBShHmfKJruaWnAtduswIh3Hy88/rXQWTBEVJFC+X93nJYf41haBfeakIK/KF/eDPerEs12NQWV1X7Dn7ynNEtHYEr6mhe3DKFVFcgkjOR8tVLS6LxbJhhgSCzD71OntvtaSx7mwWD5B61Y+zRMsQmBCjqvrUpWE2mNknN5Lh9wH3V2jmq01uEtJnjXMgH3gPmH4VW1O5it5fMhO4Z2ogbGTU8d3OVj52yNyykcfhStpcrqJMzeQs7iN5AAAWOM0kt2jMvluu4D5gprn/EcN/dxxm2Xark5BOCPwqppscywkLEyMDz6n1rWNNON7iZ0BkJmZ2cyN0VB0FY2v3cttbhomKEtggVdmulgtdy7h2OfWvNNbvpbue4XzzHt6behNbYeg6k7dEHS7OqTVbuRWzKmABwaKyNMOofYFV9iMcESMOooreVOKdtCVFvVI9MijDBkeT903OQcZovjGkKGMABRyFbmkO9r1m8tdu3lagvLbzbZ3cx4zj5TyPavOVr6l62ILe+i+2edMO4UEt1romCsBJlozxnH865yDT4WKyiMCSPG0buo+lbjSjy2PlK8hXavBySKU0r6DTFjaT7Q0imT5T8pzxiraXEUruGJEy9SeppkE0ktmyyqY8DIG3v7ViTXDC9zC5MiHBUDhqlRuDepbmE4glHzKG+VcHBGaofYJFRfJl/ejlm9DWja3kMjSCWJgU6/WrUCoiMAAX25bFUnYWxTtEnYxqsisQPugAL9auq264DIWVxwRjI/Csie8uhcm2t0ZI0GT8vY+9bVkxKRoxwxHz4PI96JLUOhLIXUKibtpXlh0z9Kk2tHaIOGcj75IBqGRESQGF1Ur8pcklvp/Lmor0b2hi3MMDIZvUCkgYMsLGWJFy54LBRnP9KrTJCZHg8sOAoJbGAx9Pc1VgV4HFyrs4LDdvOMj6VpPbtM4l3oMc7c9aLWHcQxLKpU/cxzjox9KdKAiTuEJVV4jPHb9KtOQFYRuCwwFQnGKb5B3sJGJ3A4DdM+tMVzj50uLwQiCQQSFtrjsR71v6dHJAWeKTzEgxkY+VieM0yXT4orZGn+eUscCMcZ7VZQukOx38gkZZACT9R6VUnzaINhLq2ZP37bD8pJA5I+lVwsSKkVuqhnyXZRgmieW4kvdh2/Zj0Oeas3oEjIiyGPGNwHU46Gps9gVrGVcSzRTLG20p3YckelTRRReRIeJHHzZY8g+gqKI/aL2eUvvEI2jjljiprfIsmdoAAG6MMH603psPyZbbUfImhlDonnYURMcjB7E1WmvIJtsSkDy93GcgY681LNaw31skixwgodyn1qDUrZVCyS20MES7siLILk8dKVl0C/RktmLa+vI5ra6DKPleNxkJke/FXpYkiiIuF+WPowJziuR0SW+hmZIbYraqw3MVxwCcE+vWuqv5BKY2eUbSgLx9sVUocugpO7LloInhzAAYMZJz1PrWJrczQnhf3jcKQOg9af4eu1u47lWBWHzAqKAQSvFWtVtFaRQ8JVFBXDGhqzswTszgdV1m9skROGlz8hB6g96wbfV5btJUBMk5PRm6H0FaXihQbxnMe0ICFAGeag8C6PC80ks5Vn3/cJI4r0Kcaao88lqOUuWXunW+H4roWaJeuA/GMHPGK2xakFZHG5GXjncQaqxt5S+XCiqvOQx457Cq7X1zFCFtbd3Mg4J42/UGuF+87krsaaxG1XaYQsbndwB+f1pbqBJrVjyoPylVXrWXZ6hI5XzHVpowQ2fmUnPHFbdveDhcbmYc56Ck00xdCjDY2tpGNrsxbG4A/4VKYzGXRW2W/PQ8c1VvR+/P71VBYBcDO2sq6vEhSaCSZljAJx3OO9OzkFjpEfyl8uPKEDcN/esmfXxCWWSSLcpwRuqjpWsw6gwhUOWReHPXApraYpleVlV4myMDn8zT9nyy98aaasWi1vcH5QxM2GUqAQD65q9bxGMEyy5AHAbvWNanybdckRoCRt5yAKdc3FzgNbOW8zgKRytDjrZAti9ezpD++lJZMEZ3dKzo78G3d4XCBs7c9az9ThkldIJg77uVK8DPfNVrqSOExojhBjA44zWkKSta4X2di1LK13auu7bKmQFYdT61zP9iCZEYSCOfdmQBchq3bZC8zSSOSQvLVZYgN8qbgo65zxW8Juk7RJeuqKS28uwQhztAGARRUtxKpkwVIPULnHFFJcz1DbqdWzl2EhKqgJ+6MEipHWO8i4PlqvIKfxH3pJYyLYynakSduvFI7gKBvKw44+XArhvfYq1h9ss6sBByAOSTg1LBfBXLTBfNTCkBvlA9aypL025YxTEqy8qe+a4e/1y5uNUMKbliQ4IVv51tSw7q3sNuzSPZ5HWS2RkkDDGQB1qlLaM+5oUjAA3McAE9ua5/RZXFirT3WGYfLknI9qvrcNbQIWnaZ2JwDyPpWHK1oN76CPCkRddpJYAAKeMVYtbqZY+WX5TtjDDBNS70nQGSNVIXgdDVdWQXTKP3rLg7G5/KjfcV+hNqbpDEvJDnqo65q5AmYlkEQ8wDPP8X1qndwrdw7EIhctuxjJUe1OS4ZGEALbQQQTmhq4kXDJKV2uqx7ODgZz6flRNHJdMm9dsYTaxzzn6VatHt5rwBiEXGcHkE1DqKSQyh8SAAfKVGVbvSsCYEQTxnKqzxY4A6n0qvIttYKsTM7zS5zwSBntT4XtBI7whFkYhjg9D6VDPeefqSrFFuCY3ORlR+NPzQ12ZGlj5t8k0cjoM8AnJ6dKsanPJEuHX51UnGc4xWja+VvZlaLcWJCheg+tLcQrIxlMQLAYyeppoUncwvDLO8ZkleRtzFiXxwc1oTExvcy5D84Clc1CweKVdirHsBLxnqD/KqYvbhpIvMCRwuCWdm4UjpmiWuo4lOGG/jySjyEuWO0j5F7Cp9Su1h0953Xa7Lt47n09q2LOZGjXZncDyU6Gua1qJZ9ShtI5CIgfMkBHb1qotSeoWdy74btNtojOVD53hc5IqxrE9zHNCYwrQhsvgcgVHpF3E0soVWZVO3KcjA9qj1lpIXaSaQiNz8gHORSb1swtd3JIp2AuDK+6NeI0HY+9Tl0uHiEsokAHKEdfestJHeRY2wUYAkk4raZUJRbeBWc5CuOAKTQXs7Fi3WBMlNhQ9un4VVvoI/MabZ/r/AJT6D/CpYbd5JFZgoEYyMHGcVWuJnEjuwYoQQMHPIHpQLchigPmoIQnlK+HGfmH0NS6pORbXAhcOUjO4uc1Rtbvf5dyztC2cHLf0/rT9T1G2kt9ieUWP3m/vfWnZ3sC7nBTTm5idX2iZmBjIH866TQI1t4sPHtcZJY4HUc4rMWVZL5I0SKCOM7sgZz+NdGLm3O1F8o78ZbIyMds10VHpZIcpN7ipN5jYR0K4CguetMeLY2wzLI5bgAH8azAGjaSTezyBywBHv2rai1CVnVQmGI53YBHtWTVthP0Iks7V48KfIYtyV6lvepbsjcVVixjj5ZeCTUUrMkgZFILZY8gj6VmLqZt9SMMgyJAc7j0ppOQijfW2oNAuJ0AkbnHJH1plzZxCPzppWluNuMK3B49K6LMXkDBRSjbiR3FYolid3Mcb8MRkjp9K1jN9BX0JNA0+OyXz49weRRlW64rYMjywgWaK+3JI9Ofeq+nw+TbxlptxGTuYc/SoYXN0qz2kphIkK7X43etZ1G5SuwhZLQnvA7skk8HzdeOgqJlihZ2YA7Vyr9jmrksrkqHkIXbjae1UTDtDPK29c4CZqUyrXMTVpJ4FEshZoewTmsLV3F2bZ41JkXncOn0rb3zyXMimbESt9wrU5s0KBvIGOuM11Qkqdm9ym+hjx6kkDBpVVQwCNgnr61dimhMZjV5Fkxnkdax9YsWlbzIQBscYTP61aWVlRGYqZB1I6fTFayjFxTW5D302GyztDhSu9gx3bRRQZIl3zvMpRu46g0VSXlcl+R3JlJaOdG+YdhyppszO5V7h9qLxsBxupsDRW0aKyc5wB6U28YG5R2wEJA25yDXmpF6DdQt45rZ5JCscKr2OKxbHQoDeG5eKQbWGQen41p31r9sVEJaNIZPMCgcHt/Wj7eiNINxKgj5CeuO9axnKMbRY7XeptQwQOp3KDH2A7VLBFIhkeAAJ2z1rnJNfn+1clM7QFVRgYHan22oXFxdq8xdFl/hHGMd6y9nK12N7nTCBgkc0rZuCeRngUQxxQzySxR52enY0W25F83JdBwdwxUqXCygEDbk4OOAagnYIpHfz5Y1G5VyTngCoxcPdQRyow2HIYbep7Yqk10FvJYkV89HK521p6S6mQxzwLEkRwASB+NDVgM28j1CPL2ibiBk5xwagsPEdwpe1uMJK3ByPu/jXV3EURjZ7aVd8nBH/ANaufm0pUn4QFz99ivQ/Sri42aFr1Rc+1W6wRrHHuZQe2Qx7VWhnmAJcCO2Y9AOvqKr2Mknnzx29s+6MfKScA1YlaWewJdAkyHc2R972qWraFLrc2bcQmFmgUKEGSB0HvVZpGjjbzw7fMGGB92q8ZS1SISZTn5jnGfqO9Ude1ryAWjUmKPqx6H60KLbsifNm+lwDGyw7JZeC245J9657XiYYmkSMSRgfMM9OaraNqX211kuIBDHt4kVsbq2ZPLeFyqmQnjGM/iadnF6j0TKUV8FWBfJO506Y6VHdD7ciKo/ejlyOKuOkVsqzTybXHyqdvJ/EUxp1ibasQM+d5ZyBxSvrdD6Eenxsm4SYjjUk8Dhvr6VNqkT3cESW5KsGHQcAd6q263U6zJIBFOQQOflbn+tWdP8AOxtuS4cr8uG7+3tTejErkH2IQagbhU+VkCMMYHTrVi1lQSYilYtHwQTj9KsmBlSV2uHGABt9D7+tRwWSRjzI0UtKwJbOGzj19KV7h6loNHPCy3BChTnr19qohws7xbJEQgyDYM96tTwRoWdnC7emBkMaw76/vbe5xFtKzrtGznaKErghby1WcsIiQJMbSwyRUF5oNrPAokVt/G4r2960LWR4o1FxKrEEsRj8qvi8t5LYttTDHHpVKco7Cav1PPtW8OyxyGJbqQBiArE5yKcnhNjF9na7mYqN3ynArsLiSJnjBCSRqc5bkgUkOpQSEhUjyepBrdYmpayE1c5y2cWUawOWwvyDILZxWxaLGh862KuHxleuB+NVr+NG3GH5Wc5J/unvg+tNsWEbMuwMn8JU4P1qZe8rh00LNzFAYHkWVi4B29v0rkbiW4m1KBZYCkeMbsda6lgrhWBUsvBJ6j2qteQbtxOfLOO+cH2qqclF6hqQWxhjjlSItlRkA0yA3Lr5sMOGY8DPT61e/cfZ/LRCd2DuxnGDU8caoI2RiAw+YDpmk5K7C1kULiScIjwklmJ8wOMAfSq0UhyQwPHPyjg1qS2scm6Nptp6nByaTCWsbfu9wHA9TUqStYZWt5HkgicZ2hyCGOTirFxC3mn94VWQd+VFVzch2VLdSIy3zDGMVHc3LlHMiOqICDhuCPcUrNvQrqShF+cptY5wSOgps0nyhtwxn5jWeha1UJbrkTtubj5qhY3jXccD4e2GSzvwcegrTku9xIluQGnDLIojOcZ9ayLi282SeKd5NjLwAeD7g1opIRM0iEPEvy/N2/CqCMpupG+Yt2wMVvC8dhNXMq20mF1kieSYLnhs8Citc26lSu9Yifmy3f2ord15X0kLkR2qMZCdyKAPQ9aJ40cq0nCj5sVgaTqpuLxNwKEArhQMYBxW40gkiZkyM9c+teZKLg7Mp6odFCsrEocIRgA9cepqpf2TbMKFOV29McVNZo0k2N5DY6069uVM4VkyW6n3+lCbUtBtaHEPHLb6yqpGwUdC3f2967C3tfNQz3TqpYAKo7UgRJFaaIEMDj5+cfSiSKXyRlkwG5x1NbVKnPYWttTXsZ2ijEVxJkk/Ky8jHpmrM23OQ7EA42gdfaqNv5ckIVVKHoMVPdNIJIo5CMYJyvB4rlsLzK0kxBV7fIhHDFqIHSNQIm3ozcjOcU5ESfNnlhu/i9Kkgs1bbBbgIw6se+KfMiuXQnFxO925OxYVXKuOoPsKsSakWtk+eRnmOWYDng1VnUbfLIAZDuLDvVCW5eFriYKplhAwc8ckf40KN3ohJ2RrzAqSIC29ujN6ehqlNLM14FSUlxgvxxjuP5VJPqLqbQzZffkdBxxTXjhSFi6sxL7gQcfhRsCRW1a8kWKVlDuwQrjIH4CsdIJdS01gwPmyjHlydK6iWyh8yPG4jZk57moJIDDI06n5VCjb+PatITSWm5Li9mY8Fo1haJFJG7JERjJ6k1pWz3S/aRczJkr8qr121cswPMYTqJA2OD0FSXsKRzKzLiRejL7iiUnJ2kJWSuiNZYWiigSIERruBbJJPvWXJZyPqDXUs2cnIiUYxUiSXC6kGjdBERypHPFazhDbrsUeuT1qbOJV77GdPJG05cBixwMk1JZXiFnjMfIxgnkLTb5lsJjlA7soIJ7Ummwefu8043ddvWjpdjtd2RYub82jRKkbNEMbi3Tn0q+l4ty5CrhUGQQMCsVkOz7NuPlnLAZ6EH1qhDNOHnRGG1XwwPQj0o5Lh0Na8d5YpUtXYyRnHzd6pW9srX8e/eZlXovAq2sjmcPuIUgNtFDzlZiyjkrnk9/rQnZaC62Zm6xM6R3GNkbN8qnOfzNc9Y6q1rcmymLGVmySnP411Eluk+lhpADJyd2M81mNBDbmPbGC7dTjGTW9NxSaaD0LBjkuH8yFvvH+I9vpVbT4ZLa4mExEu4hgT/DTjcMLo4CgE5wB6UFViSLDOWkJJzyKnVOwacpqb7d7fKtySWYKOM1RnM9vKZVUEFgFyOx7Vz2n3U0+pXkK7ERGGMA10km9bFZ5HaQjjafpVSg4PUlW2KralZWzPAgAL5OCaUzLIFNu3yHAIPIFeb+I71hIZdoDc4ra+HlzJNasrscA565rrlg3Gl7W5LqJSSR2du6tC/GFU9uM1K7qGzGGBZQQccfhXP6rq0toVCopAY8HpVuDV5Vt4mwMEA5781yulK1y79i2JlEweXmToc8CphIwiYgMyj5yQc8emKzSEmnnJDbpFDE1MHKmKNAArfnScRqz2JkjDspjcxNKcnPQio3WWEqkjof4WBHWo0nCzSRyLuK9CD09KguZ8KJI8llycPyDSUXcrcbLOpvVgEYMrZAlzwtTQ754WSRlbaSNwGM49KqT3pEQVo18xgDkdKWK+ykqsp3DGOOlXyu2iB6k0yJEQqlVRuo71TnYGN8xkR/7Jwaw7zVpmnMceFYcZIzSx3c8tzEJGHIIIXvXQsPJK7EQ67M8EY+yLhc4PJJ/OipNYuY0dldG+UDkGiu2g0oaxuQ2u5//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2529=[""].join("\n");
var outline_f2_30_2529=null;
var title_f2_30_2530="Circumcision PI";
var content_f2_30_2530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circumcision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 518px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circumcision is a surgery that removes the skin that covers the tip of the penis, called the \"foreskin.\" Picture A shows a boy who has not been circumcised. Picture B shows a boy who has been circumcised.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2530=[""].join("\n");
var outline_f2_30_2530=null;
var title_f2_30_2531="Large field RT portal seminoma";
var content_f2_30_2531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Large field radiation therapy for seminoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 399px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large-field (\"hockey stick\" or \"dog leg\") radiation therapy portal for a left-sided stage I seminoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clair Beard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2531=[""].join("\n");
var outline_f2_30_2531=null;
var title_f2_30_2532="Tropical filarial pulmonary eosinophilia";
var content_f2_30_2532=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tropical filarial pulmonary eosinophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2532/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/30/2532/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tropical filarial pulmonary eosinophilia (TFPE) is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by filarial nematodes (roundworms) that inhabit the lymphatics and bloodstream. Three species cause human lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori. Infection is transmitted by mosquito vectors; humans are definitive hosts.",
"   </p>",
"   <p>",
"    TFPE is caused by an immune hyperresponsiveness to microfilariae trapped in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The syndrome has been termed tropical eosinophilia, tropical pulmonary eosinophilia (TPE), or tropical filarial pulmonary eosinophilia (TFPE).",
"   </p>",
"   <p>",
"    Issues related to TFPE will be reviewed here. Issues related to lymphatic filariasis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TFPE can occur in any tropical area where filariasis occurs and is most common among young adults. It is more common in individuals from the Indian subcontinent, and occurs four to seven times more frequently in males than in females [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of cases of TFPE occur in endemic areas; cases in nonendemic settings have also been described. In a review of 17 cases observed in Toronto, all received an incorrect diagnosis at presentation (most often asthma), and a median of two consultations was required before the diagnosis was established [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3733117\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available evidence suggests that the pulmonary disease reflects a robust immunologic response against blood-borne microfilariae that become trapped within the lung and reticuloendothelial organs [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/4\">",
"     4",
"    </a>",
"    ]. TFPE develops in less than 0.5 percent of patients with lymphatic filariasis; the explanation for this observation remains unclear.",
"   </p>",
"   <p>",
"    The earliest histopathologic finding is histiocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately one month following infection, an eosinophilic interstitial infiltrate develops. In more severe cases, eosinophilic abscesses, eosinophilic bronchopneumonia, or eosinophilic granulomas may be observed. With chronic disease there is an ongoing eosinophil interstitial infiltration and increasing pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/1\">",
"     1",
"    </a>",
"    ]. Occasionally microfilarial fragments may be identifiable in biopsied lung or reticuloendothelial tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of clinical manifestations is usually gradual. Symptoms include a dry, hacking, nonproductive cough which is frequently paroxysmal and nocturnal. Asthma-like attacks are associated with breathlessness and wheezing. Other symptoms include weight loss, fatigue, and malaise. Dyspnea on exertion is relatively uncommon.",
"   </p>",
"   <p>",
"    Chest findings are minimal or absent in most patients. In some cases, rhonchi, crepitations (especially over the midzones and bases), and wheezing may be auscultated. Lymphadenopathy, hepatomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly are observed in approximately 15 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal laboratory finding in tropical filarial pulmonary eosinophilia (TFPE) is blood eosinophilia, usually above",
"    <span class=\"nowrap\">",
"     3000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/6\">",
"     6",
"    </a>",
"    ]. An elevation in serum IgE level is frequently observed, often above 1000",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"    The diagnosis can be confirmed by marked elevations in filarial antibody titers. Microfilariae are generally not detectable in peripheral blood and circulating filarial antigen is undetectable in up to 50 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/8\">",
"     8",
"    </a>",
"    ]. Bronchoalveolar lavage reveals an intense eosinophilic alveolitis in patients with active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major chest x-ray findings include increased bronchoalveolar markings, diffuse interstitial lesions (1 to 3 mm in diameter),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mottled opacities (usually most prominent in the lower lung fields) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75859 \" href=\"UTD.htm?14/56/15234\">",
"     image 1",
"    </a>",
"    ). Hilar lymphadenopathy and pleural effusions are rare. The chest x-ray is normal in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary function tests (PFTs) typically demonstrate a predominantly restrictive pattern together with mild to moderate airway obstruction. In some cases, PFTs demonstrate a predominantly obstructive pattern with a mild restrictive component [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ]. Airway obstruction is reversible with bronchodilators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8335358\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of TFPE includes chronic eosinophilic pneumonia, drug hypersensitivity reactions, military tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/9\">",
"     9",
"    </a>",
"    ], fungal pneumonia, and pulmonary syndromes associated with other helminths (most commonly Toxocara hookworm, Ascaris, and Strongyloides) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/10\">",
"     10",
"    </a>",
"    ]. Among these, tuberculosis and strongyloidiasis are most important to exclude since corticosteroid administration can lead to fatal dissemination of infection. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard treatment consists of diethylcarbamazine (DEC) given at 6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in three doses for 12 to 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. DEC is active against both the microfilariae and adult worms, and DEC therapy is associated with a dramatic and rapid improvement in signs and symptoms in most cases. The restrictive and obstructive defects typically return toward normal if DEC is administered in the first few years of disease, although a low-grade eosinophilic alveolitis may persist [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/13\">",
"     13",
"    </a>",
"    ]. If DEC therapy is delayed, progressive interstitial fibrosis and irreversible impairment in pulmonary function can occur.",
"   </p>",
"   <p>",
"    Corticosteroid therapy has been used as adjunctive therapy to reduce inflammation in the acute setting but is not definitive therapy for tropical filarial pulmonary eosinophilia (TFPE).",
"   </p>",
"   <p>",
"    Relapses occur in up to 20 percent of patients within the first five years of DEC therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/5\">",
"     5",
"    </a>",
"    ] and are treated with a repeat course of the same treatment regimen.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for six weeks) also has efficacy against adult filarial worms through its action on their Wolbachia endosymbionts [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2532/abstract/13\">",
"     13",
"    </a>",
"    ], there are no trials evaluating the efficacy of doxycycline as either primary or adjunctive treatment for TFPE. Bronchospasm can generally be managed with bronchodilators, although short-term corticosteroids may be necessary in severe cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DEC is not distributed for use in the United States but can be obtained from the Centers for Disease Control and Prevention (CDC) under an Investigational New Drug (IND) protocol (Centers for Disease Control and Prevention Drug Service, Atlanta, GA 30333; telephone 404-639-2888). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link&amp;anchor=H3730443#H3730443\">",
"     \"Diagnosis, treatment, and prevention of lymphatic filariasis\", section on 'Individuals in areas with low or no transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3037715\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tropical filarial pulmonary eosinophilia (TFPE) is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by nematodes (roundworms) that inhabit the lymphatics and bloodstream. TFPE is caused by an immune hyperresponsiveness to microfilariae that become trapped in the lungs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TFPE can occur in any tropical area where filariasis occurs and is most common among young adults. It is more common in individuals from the Indian subcontinent, and occurs four to seven times more frequently in males than in females. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of clinical manifestations is usually gradual. Symptoms include a dry, hacking, nonproductive cough that is frequently paroxysmal and nocturnal. Asthma-like attacks are associated with breathlessness and wheezing. Other symptoms include weight loss, fatigue, and malaise. Dyspnea on exertion is relatively uncommon. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal laboratory finding in TFPE is blood eosinophilia, usually above",
"      <span class=\"nowrap\">",
"       3000/microL.",
"      </span>",
"      An elevation in serum IgE level is frequently observed, often above 1000",
"      <span class=\"nowrap\">",
"       units/mL.",
"      </span>",
"      The diagnosis can be confirmed by elevations in filarial antibody titers. Microfilariae are generally not detectable in peripheral blood. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of TFPE, we recommend diethylcarbamazine (6",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      in three doses for 12 to 21 days) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Bronchospasm can be managed with bronchodilators and, in severe cases, short-term corticosteroids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201053228\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors at UpToDate, Inc. would like to acknowledge Peter Weller, MD, FACP, and Karin Leder, MBBS, FRACP, PhD, MPH, DTMH, who contributed to an earlier version of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/1\">",
"      Vijayan VK. Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. Curr Opin Pulm Med 2007; 13:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/2\">",
"      Weingarten RJ. Tropical eosinophilia. Lancet 1943; 1:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/3\">",
"      Pinkston P, Vijayan VK, Nutman TB, et al. Acute tropical pulmonary eosinophilia. Characterization of the lower respiratory tract inflammation and its response to therapy. J Clin Invest 1987; 80:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/4\">",
"      Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia. Annu Rev Med 1992; 43:417.",
"     </a>",
"    </li>",
"    <li>",
"     Udwadia FE. Tropical eosinophilia. In: Progress in Respiration Research: Pulmonary Eosinophilia, Udwadia FE (Ed), Karger, New York 1975. p.35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/6\">",
"      Ong RK, Doyle RL. Tropical pulmonary eosinophilia. Chest 1998; 113:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/7\">",
"      Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clin Infect Dis 2004; 39:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/8\">",
"      Lal RB, Paranjape RS, Briles DE, et al. Circulating parasite antigen(s) in lymphatic filariasis: use of monoclonal antibodies to phosphocholine for immunodiagnosis. J Immunol 1987; 138:3454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/9\">",
"      Ray S, Kundu S, Goswami M, Maitra S. Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. Parasitol Int 2012; 61:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/10\">",
"      Rocha A, Dreyer G, Poindexter RW, Ottesen EA. Syndrome resembling tropical pulmonary eosinophilia but of non-filarial aetiology: serological findings with filarial antigens. Trans R Soc Trop Med Hyg 1995; 89:573.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, Med Lett Drug Ther, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/12\">",
"      Fernando SD, Rodrigo C, Rajapakse S. Current evidence on the use of antifilarial agents in the management of bancroftian filariasis. J Trop Med 2011; 2011:175941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2532/abstract/13\">",
"      Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5711 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2532=[""].join("\n");
var outline_f2_30_2532=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3037715\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3733117\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8335358\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3037715\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H201053228\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5711\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5711|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/56/15234\" title=\"diagnostic image 1\">",
"      Chest x-ray - tropical pulmonary eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13719?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of lymphatic filariasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2533="Ketoconazole (systemic): Patient drug information";
var content_f2_30_2533=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketoconazole (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=see_link\">",
"     see \"Ketoconazole (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=see_link\">",
"     see \"Ketoconazole (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ketoconazole&reg;;",
"     </li>",
"     <li>",
"      Novo-Ketoconazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketoconazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a yeast infection of the brain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696829",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids or sucralfate within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699461",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12233 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2533=[""].join("\n");
var outline_f2_30_2533=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120609\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027607\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027609\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027608\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027613\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027614\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027616\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027611\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027612\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027617\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027618\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2534="Drospirenone and estradiol: Patient drug information";
var content_f2_30_2534=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Drospirenone and estradiol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21719?source=see_link\">",
"     see \"Drospirenone and estradiol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1884104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Angeliq&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat vaginal irritation and dryness caused by change of life.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702056",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estradiol, drospirenone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding disorder, blood clots, breast cancer, kidney disease, liver disease, poor adrenal function, stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you do not have a uterus and are using this drug to treat signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697924",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11528 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2534=[""].join("\n");
var outline_f2_30_2534=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1884104\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935275\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026999\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027001\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027000\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027005\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027006\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027008\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027003\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027004\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027009\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027010\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21719?source=related_link\">",
"      Drospirenone and estradiol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2535="Trichotillomania";
var content_f2_30_2535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Trichotillomania",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hairs tend to be broken at different lengths. The areas of alopecia are not completely devoid of hair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2535=[""].join("\n");
var outline_f2_30_2535=null;
var title_f2_30_2536="Mitochondrial myopathies: Treatment";
var content_f2_30_2536=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitochondrial myopathies: Treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Angela Genge, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Rami Massie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2536/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2536/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/30/2536/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial diseases are caused by pathologic dysfunction of the mitochondrial respiratory chain. They present with a wide range of clinical expression. The organ systems most reliant on aerobic metabolism are preferentially affected. Myopathy may be the sole or main sign, or merely an incidental finding associated with a multisystemic illness. Involvement of the nervous system in general (referred to as mitochondrial encephalomyopathy) is common. When skeletal muscle is affected, either alone or with central nervous system disease, the term mitochondrial myopathy is used.",
"   </p>",
"   <p>",
"    The following groups illustrate the different ways mitochondrial myopathies can present clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      As chronic progressive external ophthalmoplegia (with or without mild proximal muscle weakness) or Kearns-Sayre syndrome",
"     </li>",
"     <li>",
"      As an isolated myopathy with or without exercise intolerance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myalgia",
"     </li>",
"     <li>",
"      As a severe myopathy or encephalomyopathy of infancy and childhood",
"     </li>",
"     <li>",
"      As a predominantly multisystem disease (eg, MELAS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A certain degree of overlap exists between all these entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link&amp;anchor=H3#H3\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite considerable advances in the genetics and molecular biology of mitochondrial disorders, the mainstay of current treatment remains supportive. Many pharmacologic agents have been tried in case reports or small series, and a few have been tested in randomized controlled trials. While some of these agents appear to be beneficial for various surrogate measures, none has demonstrated a long-term benefit for clinically important outcomes.",
"   </p>",
"   <p>",
"    This topic will first discuss symptomatic therapies and review the evidence for the pharmacologic agents. We will divide the pharmacologic agents by presumed mechanism of action, concentrating on those with more robust or more promising evidence. Finally, future targets for gene therapy will be introduced.",
"   </p>",
"   <p>",
"    Other aspects of mitochondrial myopathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=see_link\">",
"     \"Mitochondrial structure, function, and genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of current treatment for patients with mitochondrial myopathies is supportive. Depending on the degree of impairment and the extent of neurologic involvement, the following evaluations and interventions may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory care - This is often a life-saving or life-sustaining measure in patients with chronic respiratory failure. A discussion of respiratory or sleep-related symptoms should occur regularly with the patient and family. Pulmonary function tests should be obtained at baseline and again as clinically indicated when symptoms appear. Interventions include noninvasive measures such as continuous positive air pressure (CPAP) and bilevel positive air pressure (BiPAP). Some patients may eventually require tracheostomy [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Control of seizures - Standard anticonvulsant therapy can be used to control seizures. An exception is that valproic acid and its derivatives should be avoided if possible because they inhibit the biosynthesis of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      , potentially leading to impaired mitochondrial beta-oxidation and fatty acid metabolism.",
"     </li>",
"     <li>",
"      Cardiologic assessment - for cardiomyopathy and conduction defects.",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation - Ptosis can be treated with frontalis muscle-eyelid suspension, levator palpebrae resection, eyelid crutches, or blepharoplasty. Cataracts are treated with intraocular lens replacement. Ophthalmoplegia usually does not require any specific intervention, but can be addressed by glasses with corrective prisms when accompanied by significant diplopia. Strabismus surgery is also an option if the degree of ophthalmoplegia is stable for at least six months on serial measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Audiologic evaluation - Sensorineural hearing loss can be addressed with cochlear implants. Aminoglycosides should be avoided [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Drugs to avoid'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Screening for diabetes mellitus - Diabetes can be managed with dietary modification, oral agents, or insulin as appropriate. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      should be avoided because it has been associated with lactic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21799?source=see_link&amp;anchor=H5#H5\">",
"       \"Metformin poisoning\", section on 'Lactic acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Multidisciplinary speech, physical, and occupational therapy - This can be helpful for patients with central nervous system deficits such as dysarthria, dysphagia, weakness, spasticity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive evaluation and appropriate intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise appears to be beneficial in mitochondrial disorders. Aerobic exercise has been associated with increased peak work, oxidative capacity, and mitochondrial volume [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In addition, aerobic exercise can prevent muscle deconditioning and decrease exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also some evidence that the response to resistance training exercise can alter the proportion of mutant and wild-type mitochondrial DNA (ie, gene shifting) in regenerated muscle fibers by activating wild-type satellite cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ]. However, it is not clear whether this is a viable strategy to reduce the burden of mutant mitochondrial DNA in muscle and thereby improve muscle function.",
"   </p>",
"   <p>",
"    Given these data, we suggest routine moderate level aerobic exercise (eg, walking, running, cycling, or swimming) for patients with mitochondrial disorders who are able to participate in physical activity combined with resistance strength training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven effective therapy for the primary mitochondrial disorders. Pharmacologic strategies that have been tested for these conditions include the use of respiratory chain cofactors, treatment with antioxidants, trials of agents that correct secondary biochemical deficits, and therapy with drugs that reduce lactic acid accumulation. Much of the evidence comes from single case reports and small open-label studies. A systematic review published in 2012 identified 12 randomized controlled trials that evaluated pharmacologic agents for mitochondrial diseases, but no clear evidence was found to support the use of any intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not established as effective for mitochondrial disorders, our typical regimen for adults and adolescents is coenzyme Q10 (400 mg daily), creatine 10 g daily, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (990 mg daily in three divided doses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Respiratory chain cofactors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Succinate, riboflavin, thiamine, and coenzyme Q10 participate as cofactors in the electron transport chain enzymes (",
"    <a class=\"graphic graphic_figure graphicRef67253 \" href=\"UTD.htm?11/55/12148\">",
"     figure 1",
"    </a>",
"    ). Supplementation is thought to enhance the activity of these enzymes when they are deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although evidence of possible modest benefit with coenzyme Q10 is sparse, we suggest it for patients with primary mitochondrial disorders, as discussed in the next section. However, there is no evidence that supplementation with succinate, riboflavin, or thiamine is useful for improving function or outcome in patients with primary mitochondrial disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Coenzyme Q10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 has been evaluated in small randomized controlled trials, with equivocal results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial was a placebo-controlled blinded crossover design that evaluated 30 patients with various mitochondrial encephalomyopathies, including 15 with mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) and 11 with chronic progressive external ophthalmoplegia [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/15\">",
"       15",
"      </a>",
"      ]. Treatment with coenzyme Q10 (1200 mg daily) for 60 days did",
"      <strong>",
"       not",
"      </strong>",
"      lead to improvement in clinical measures such as grip strength, activities of daily living, or quality of life but did increase oxygen uptake (VO2) after 15 minutes of exercise and attenuated the rise in lactate.",
"     </li>",
"     <li>",
"      Another double-blind crossover trial evaluated eight patients with various mitochondrial encephalomyopathies, including three with MELAS, who took coenzyme Q10 (160",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for three months and placebo for one month, followed by a one month wash out period [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/16\">",
"       16",
"      </a>",
"      ]. Coenzyme Q10 treatment led to a statistically significant increase in a global scale of muscle strength and an increase in serum levels of coenzyme Q10.",
"     </li>",
"     <li>",
"      The earliest trial evaluated 17 patients with chronic progressive external ophthalmoplegia and was negative [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An ongoing placebo-controlled trial is evaluating coenzyme Q10 for children with a mutation in mtDNA or nuclear DNA associated with dysfunction of the respiratory chain or the electron transport chain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coenzyme Q10 is both an antioxidant (as discussed in the next section) and an integral part of the mitochondrial respiratory chain, where it acts as an electron acceptor. It is uncertain which (if either) of these roles is beneficial when coenzyme Q10 supplementation is used for patients with mitochondrial disorders. However, for patients with coenzyme Q10 deficiency, benefit probably derives from its function as an electron carrier [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Coenzyme Q10 deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the evidence of modest benefit in one trial, and the lack of serious side effects, we suggest treatment with coenzyme Q10 for patients with mitochondrial disorders. The suggested dose is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for infants and children and 400 mg daily for adolescents and adults. Higher doses are suggested for patients who have mitochondrial disease with coenzyme Q10 deficiency. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Coenzyme Q10 deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial diseases in general result in an increase in oxidative stress and higher levels of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/19\">",
"     19",
"    </a>",
"    ]. This may cause damage to the cell membrane through lipid peroxidation.",
"   </p>",
"   <p>",
"    A number of antioxidants have been used to treat patients with mitochondrial myopathies, with the rationale that scavenging reactive oxygen species would lead to clinical improvement. The list includes coenzyme Q10, idebenone (a coenzyme Q10 analog), vitamin E, and dihydrolipoate. While some observational reports suggested partial improvement in clinical function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical parameters in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], there is no convincing evidence that use of these agents leads to a clinically meaningful benefit. The equivocal evidence regarding coenzyme Q10 is discussed above. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Coenzyme Q10'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Correcting secondary biochemical deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    , creatine, and folate are decreased in patients with mitochondrial disorders, although the exact mechanisms are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Given the relative harmless effect of their supplementation, they are often given as part of a \"mitochondrial cocktail\" to patients. However, there is no compelling evidence that supplementation of these agents produces a clinically important benefit. Nevertheless, we suggest treatment with creatine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    for patients with mitochondrial disorders, as discussed in the next sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Creatine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small trials tested creatine for mitochondrial disorders, with conflicting results.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a placebo-controlled crossover trial involving six patients (five with MELAS and one with a mitochondrial myopathy), treatment with creatine (10",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for two weeks followed by 4",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for one week) resulted in improvement in some variables, including a statistically significant 20 percent increase in hand grip strength [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/25\">",
"       25",
"      </a>",
"      ]. However, there was no improvement in activities of daily living.",
"     </li>",
"     <li>",
"      A second placebo-controlled crossover trial involving 16 patients with a mitochondrial disorder (including 13 with chronic progressive external ophthalmoplegia) found no significant benefit after four weeks with high dose creatine (20 g daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another placebo-controlled crossover trial that analyzed results from 16 patients with various mitochondrial disorders, treatment with a combination of creatine, coenzyme Q10, and lipoic acid resulted in a reduction of serum lactate and a reduction in the decline of peak ankle dorsiflexion strength [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there was no effect on pulmonary function, or on peak handgrip or knee extension strength.",
"   </p>",
"   <p>",
"    Given the evidence from at least one controlled trial of possible modest benefit, and its relative lack of side effects, we suggest creatine to most of our patients with mitochondrial encephalomyopathies.",
"   </p>",
"   <p>",
"    The optimal creatine dose is uncertain. For adolescents and adults, one trial used 10 g daily for the first two weeks, followed by 4 g daily for maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/25\">",
"     25",
"    </a>",
"    ]. However, cramps can be a problem at such high doses. For that reason, we usually start creatine at 4.5 g daily given in three divided doses, and titrate it up as tolerated, with a maximum total daily dose of 10 g. For infants and young children, creatine doses from 0.08 to 0.35",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    daily have been used [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    (levocarnitine) has not been studied in controlled trials in the context of primary mitochondrial respiratory chain disorders. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    supplementation can be almost curative in primary systemic carnitine deficiency, which typically presents in childhood with dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of metabolic myopathies\", section on 'Systemic carnitine deficiency with cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     L-carnitine",
"    </a>",
"    because it is generally safe and may help to correct an underlying deficiency of free",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1\">",
"     1",
"    </a>",
"    ]. The suggested dose for adolescents and adults is L-carnitine 1000 mg daily in the morning. The suggested dose for children is 100 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in four divided doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reducing lactic acid accumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe deficiency in enzymes of the respiratory chain can lead to accumulation of upstream substrates such as lactate, which is considered a neurotoxic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, attempts at reducing serum lactate with bicarbonate showed only transient buffering effects with worsening of cerebral function [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, controlled trials have not shown benefit for agents that reduce the accumulation of lactic acid.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dichloroacetate increases the activity of pyruvate dehydrogenase, which allows pyruvate to be oxidized rather than being converted to lactate. However, results from three randomized placebo-controlled trials of dichloroacetate were disappointing [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. The first trial involved 11 patients with mitochondrial diseases and failed to show any clinical improvement in muscle strength or disability [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/32\">",
"       32",
"      </a>",
"      ]. The second trial was stopped early because nearly all patients treated with dichloroacetate developed a polyneuropathy in the absence of any clear benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/33\">",
"       33",
"      </a>",
"      ]. The third trial found no improvement in neurologic or other measures of clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dimethylglycine, another agent known to decrease serum lactate, did not have any effect on oxygen consumption or several biochemical parameters of disease in a placebo-controlled crossover trial involving five children with the French-Canadian type of Leigh syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Select mitochondrial disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 deficiency is responsive to high-dose coenzyme Q10 therapy. Preliminary studies suggest that MELAS is responsive to l-arginine, but efficacy has not been established. The evidence is presented in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Coenzyme Q10 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coenzyme Q10 deficiency is a rare, clinically and genetically heterogeneous condition that can manifest in several ways. Reported presentations include an isolated myopathy with exercise intolerance, a myopathy with associated central neurologic manifestations (eg, ataxia and seizures), a severe encephalomyopathy of infancy (ie, Leigh syndrome), or an isolated progressive ataxia syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Distinction should be made between primary deficiency caused by mutations in nuclear genes controlling coenzyme Q10 synthesis and secondary deficiency caused by other disorders of the respiratory chain. In one series of 76 patients with heterogeneous mitochondrial phenotypes, muscle coenzyme Q10 content was below normal for 28 patients, and nine of those patients were categorized as having secondary coenzyme Q10 deficiency because they had mutations in genes not involved in coenzyme Q10 biosynthetic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While treatment seems clearly indicated in primary deficiency, the majority of cases involve secondary deficiency, which may also respond to supplementation regardless of the underlying mutation. In all reported forms, there is observational evidence that high-dose oral coenzyme Q10 treatment is associated with clinically meaningful improvement in muscle function in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. Furthermore, coenzyme Q10 treatment can be life-saving in infants with encephalomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1,42,43\">",
"     1,42,43",
"    </a>",
"    ]. However, central nervous system manifestations may be only partially reversible or may continue to progress despite treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/37,44,45\">",
"     37,44,45",
"    </a>",
"    ]. Anecdotal evidence suggests that treatment prior to the onset of overt neurologic symptoms (age 12 months in the reported case) can prevent neurologic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend high-dose oral coenzyme Q10 treatment for patients with coenzyme Q10 deficiency. Suggested coenzyme Q10 dosing is 5 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily (in three divided doses) for infants and children, 300 to 1500 mg daily for adolescents, and up to 2400 mg daily for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/37,42,43\">",
"     37,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myopathies or encephalomyopathies related to coenzyme Q10 deficiency tend to respond well at lower doses of coenzyme Q10. However, patients with ataxic presentation usually require a higher dose of coenzyme Q10 (up to 3000 mg daily) and do not respond as well, possibly due to cerebellar neuronal death [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     MELAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MELAS is one of the most common mitochondrial disorders, but no specific disease-modifying therapy is available. In two small trials discussed above that included some patients with MELAS, there was marginal improvement on some outcome measures with coenzyme Q10 treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/16\">",
"     16",
"    </a>",
"    ] and with creatine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of stroke-like episodes in MELAS is uncertain but may be related to regional metabolic energy failure. Another hypothesis is that an impairment of cerebral artery vasodilation may cause or exacerbate these episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/1,46\">",
"     1,46",
"    </a>",
"    ]. If so, arginine could have a therapeutic effect because it is a precursor of nitric oxide, an important mediator of cerebral vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/46\">",
"     46",
"    </a>",
"    ]. Furthermore, a small case-control study found that the mean serum level of arginine was significantly lower in patients with MELAS than in healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an open-label pilot study, l-arginine infusion (0.5",
"    <span class=\"nowrap\">",
"     g/kg)",
"    </span>",
"    or placebo was given in an approximately 2:1 ratio during the acute phase of 34 stroke-like episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/47\">",
"     47",
"    </a>",
"    ]. L-arginine was associated with a statistically significant short-term (24 hours) improvement in clinical symptoms. In the same study, oral l-arginine (4 to 24 g daily) was given to six patients with MELAS for 18 months, with a reduction in the frequency and severity of stroke symptoms compared with baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these data appear promising, rigorous controlled trials are needed to establish whether arginine treatment provides lasting benefit in MELAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Drugs to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs may interfere with respiratory chain function, including valproic acid and its derivatives, barbiturates, tetracyclines, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    . These medications generally should be avoided for patients with primary mitochondrial disorders.",
"   </p>",
"   <p>",
"    In addition, aminoglycosides should be avoided in patients with multisystem mitochondrial disorders because such patients are at increased risk of hearing loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=see_link\">",
"     \"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    should also be avoided because its major toxicity is lactic acidosis. This may be particularly important for patients with mitochondrial disorders who have undetected cardiomyopathy, a condition that probably increases the risk of metformin-induced lactic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21799?source=see_link&amp;anchor=H5#H5\">",
"     \"Metformin poisoning\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of effective pharmacologic agents for mitochondrial disorders, research into improved treatment has concentrated on gene therapy. However, therapeutic modification of the mitochondrial genome presents challenges beyond those seen in disorders of nuclear DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/48\">",
"     48",
"    </a>",
"    ]. In particular, heteroplasmy and the presence of multiple genomes in even single cells have complicated current research. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=see_link\">",
"     \"Mitochondrial structure, function, and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approaches discussed here are not standard therapy and have been studied in preclinical models only. A number of different techniques are being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Some of these methods aim to increase the ratio of wild-type DNA to mutant DNA and to manipulate the level of heteroplasmy in the cell or the tissue, a method known as \"gene shifting&rdquo;. Several strategies employ delivery of wild-type version of the defective mitochondrial-encoded gene or delivery of foreign tRNA into the mitochondria in order to improve mitochondrial function and ameliorate progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another approach consists of replacing the mutated mitochondrial DNA of the oocyte with a healthy mitochondrial genome from a donated oocyte. This can be accomplished by removing the cytoplasmic contents (and hence all the abnormal mitochondria) from the mother's fertilized oocytes, transferring the nuclear content of these oocytes to a normal \"enucleated\" oocyte from a donor woman, and replacing it in the mother's uterus [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2536/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The newborn baby would have all the nuclear genetic components of his parents but mitochondrial DNA from a donor woman.",
"   </p>",
"   <p>",
"    Evidence that exercise can alter the ratio of wild-type DNA to mutant DNA in muscle is presented above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Exercise'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mainstay of current treatment for patients with mitochondrial disease remains supportive. Issues that may require evaluation and intervention include respiratory failure, seizures, cardiomyopathy and conduction defects, ophthalmoplegia, ptosis, cataracts, hearing loss, diabetes mellitus, neurologic deficits (including dysarthria, dysphagia, weakness, spasticity,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ataxia) and cognitive impairment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Symptomatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mitochondrial disorders who are able to participate in physical activity, we suggest routine, moderate level aerobic exercise and regular mild resistance training (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options for aerobic exercise include walking, running, cycling, or swimming. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no proven pharmacologic therapy for the primary mitochondrial disorders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with mitochondrial disorders, we suggest combination treatment with coenzyme Q10, creatine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Our typical regimen for adults and adolescents is coenzyme Q10 400 mg daily, creatine 4 to 10 g daily in three divided doses, and L-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      990 mg daily in three divided doses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Coenzyme Q10'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Creatine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Carnitine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with coenzyme Q10 deficiency, we recommend high-dose oral coenzyme Q10 treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Coenzyme Q10 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with primary mitochondrial disorders should avoid certain drugs if possible, including valproic acid and its derivatives, barbiturates, tetracyclines,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      , aminoglycosides, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Drugs to avoid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/1\">",
"      DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34:265.",
"     </a>",
"    </li>",
"    <li>",
"     Chinnery PF. Mitochondrial disorders overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1224/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/3\">",
"      Kisler JE, Whittaker RG, McFarland R. Mitochondrial diseases in childhood: a clinical approach to investigation and management. Dev Med Child Neurol 2010; 52:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/4\">",
"      Edmonds JL Jr. Surgical and anesthetic management of patients with mitochondrial dysfunction. Mitochondrion 2004; 4:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/5\">",
"      Bau V, Zierz S. Update on chronic progressive external ophthalmoplegia. Strabismus 2005; 13:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/6\">",
"      McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurol 2002; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/7\">",
"      Millhouse-Flourie TJ. Physical, occupational, respiratory, speech, equine and pet therapies for mitochondrial disease. Mitochondrion 2004; 4:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/8\">",
"      Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain 2006; 129:3402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/9\">",
"      Trenell MI, Sue CM, Kemp GJ, et al. Aerobic exercise and muscle metabolism in patients with mitochondrial myopathy. Muscle Nerve 2006; 33:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/10\">",
"      Taivassalo T, Shoubridge EA, Chen J, et al. Aerobic conditioning in patients with mitochondrial myopathies: physiological, biochemical, and genetic effects. Ann Neurol 2001; 50:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/11\">",
"      Cejudo P, Bautista J, Montemayor T, et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. Muscle Nerve 2005; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/12\">",
"      Shoubridge EA, Johns T, Karpati G. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. Hum Mol Genet 1997; 6:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/13\">",
"      Murphy JL, Blakely EL, Schaefer AM, et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/14\">",
"      Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4:CD004426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/15\">",
"      Glover EI, Martin J, Maher A, et al. A randomized trial of coenzyme Q10 in mitochondrial disorders. Muscle Nerve 2010; 42:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/16\">",
"      Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 1997; 37:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/17\">",
"      Muller W, Reimers CD, Berninger T. Coenzyme Q10 in ophthalmoplegia plus - a double blind cross over therapeutic trial. J Neurol Sci 1990; 98 Suppl:442.",
"     </a>",
"    </li>",
"    <li>",
"     Phase III trial of coenzyme Q10 in mitochondrial disease. file://clinicaltrials.gov/ct2/show/NCT00432744 (Accessed on May 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/19\">",
"      Esposito LA, Melov S, Panov A, et al. Mitochondrial disease in mouse results in increased oxidative stress. Proc Natl Acad Sci U S A 1999; 96:4820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/20\">",
"      Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996; 47:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/21\">",
"      Bakker HD, Scholte HR, Jeneson JA. Vitamin E in a mitochondrial myopathy with proliferating mitochondria. Lancet 1993; 342:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/22\">",
"      Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995; 242:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/23\">",
"      Allen RJ, DiMauro S, Coulter DL, et al. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983; 13:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/24\">",
"      Melegh B, Seress L, Bedekovics T, et al. Muscle carnitine acetyltransferase and carnitine deficiency in a case of mitochondrial encephalomyopathy. J Inherit Metab Dis 1999; 22:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/25\">",
"      Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997; 20:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/26\">",
"      Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 2000; 55:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/27\">",
"      Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/28\">",
"      Komura K, Hobbiebrunken E, Wilichowski EK, Hanefeld FA. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr Neurol 2003; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/29\">",
"      Artuch R, Vilaseca MA, Pineda M. Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis 1998; 21:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/30\">",
"      Kaufmann P, Shungu DC, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004; 62:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/31\">",
"      Horvath R, Gorman G, Chinnery PF. How can we treat mitochondrial encephalomyopathies? Approaches to therapy. Neurotherapeutics 2008; 5:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/32\">",
"      De Stefano N, Matthews PM, Ford B, et al. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995; 45:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/33\">",
"      Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006; 66:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/34\">",
"      Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006; 117:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/35\">",
"      Liet JM, Pelletier V, Robinson BH, et al. The effect of short-term dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a double-blind randomized crossover clinical trial. J Pediatr 2003; 142:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/36\">",
"      Artuch R, Salviati L, Jackson S, et al. Coenzyme Q10 deficiencies in neuromuscular diseases. Adv Exp Med Biol 2009; 652:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/37\">",
"      Emmanuele V, L&oacute;pez LC, L&oacute;pez L, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol 2012; 69:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/38\">",
"      Sacconi S, Trevisson E, Salviati L, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010; 20:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/39\">",
"      Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/40\">",
"      Lalani SR, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005; 62:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/41\">",
"      Horvath R, Schneiderat P, Schoser BG, et al. Coenzyme Q10 deficiency and isolated myopathy. Neurology 2006; 66:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/42\">",
"      R&ouml;tig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000; 356:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/43\">",
"      Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005; 65:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/44\">",
"      Aur&eacute; K, Benoist JF, Ogier de Baulny H, et al. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 2004; 63:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/45\">",
"      Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med 2008; 358:2849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/46\">",
"      Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 2002; 58:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/47\">",
"      Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005; 64:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/48\">",
"      Adhya S, Mahato B, Jash S, et al. Mitochondrial gene therapy: The tortuous path from bench to bedside. Mitochondrion 2011; 11:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/49\">",
"      Scarpelli M, Cotelli MS, Mancuso M, et al. Current options in the treatment of mitochondrial diseases. Recent Pat CNS Drug Discov 2010; 5:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/50\">",
"      Tachibana M, Amato P, Sparman M, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/51\">",
"      Tachibana M, Sparman M, Mitalipov S. Chromosome transfer in mature oocytes. Nat Protoc 2010; 5:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2536/abstract/52\">",
"      Paull D, Emmanuele V, Weiss KA, et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013; 493:632.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5149 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2536=[""].join("\n");
var outline_f2_30_2536=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMATIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Respiratory chain cofactors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Coenzyme Q10",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Correcting secondary biochemical deficits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Creatine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Carnitine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reducing lactic acid accumulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Select mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Coenzyme Q10 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - MELAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Drugs to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5149\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5149|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/55/12148\" title=\"figure 1\">",
"      Mitochondrial pathways",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21799?source=related_link\">",
"      Metformin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=related_link\">",
"      Mitochondrial structure, function, and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18072?source=related_link\">",
"      Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2537="Elevated cardiac troponin concentration in the absence of an acute coronary syndrome";
var content_f2_30_2537=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2537/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2537/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2537/contributors\">",
"     David A Morrow, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2537/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2537/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2537/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2537/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/30/2537/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an acute myocardial infarction (MI) has traditionally relied upon the combination of chest pain, electrocardiographic (ECG) abnormalities, and elevations in serum biomarkers of cardiac injury. Symptoms and ECG abnormalities, however, may be absent or nonspecific. Thus, the diagnosis of an acute MI has increasingly depended upon evaluation of cardiac biomarkers, particularly cardiac troponins.",
"   </p>",
"   <p>",
"    The 2007 Joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation",
"    <span class=\"nowrap\">",
"     (ESC/ACCF/AHA/WHF)",
"    </span>",
"    Task Force for the definition of myocardial infarction emphasized the importance of both elevated cardiac biomarkers and clinical evidence for myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/1\">",
"     1",
"    </a>",
"    ]. This expert consensus document suggests that the term myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. In this setting, detection of rise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the upper reference limit is one of the criteria to diagnose myocardial infarction together with symptomatic, electrocardiographic or echocardiographic evidence of myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical evidence of myocardial ischemia is necessary because serum troponin elevations may reflect myocardial injury that is not necessarily due to an acute coronary syndrome (ACS). They can also be seen in a variety of other diseases, such as sepsis, hypovolemia, atrial fibrillation, heart failure, pulmonary embolism, myocarditis, myocardial contusion, and renal failure.",
"   </p>",
"   <p>",
"    Among patients with a high pretest probability of thrombotic coronary heart disease (CHD), the value of troponin for diagnosis, risk assessment, and therapeutic decision making is clear. However, in patients with a low pretest probability of CHD, troponin elevations are not specific to acute thrombotic disease and may, in some cases, divert attention from the true underlying clinical problem and lead to unnecessary invasive cardiac testing.",
"   </p>",
"   <p>",
"    Potential causes of troponin elevation unrelated to coronary thrombosis, and the evaluation and management of patients with these conditions will be reviewed here. The biochemical characteristics of troponins and the utility of troponins for the diagnosis of acute MI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H3#H3\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Troponins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link\">",
"     \"Excitation-contraction coupling in myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Cardiac biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CARDIAC TROPONINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponins are regulatory proteins that control the calcium-mediated interaction of actin and myosin. The troponin complex consists of 3 subunits, troponin T (cTnT), troponin I (cTnI), and troponin C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=see_link&amp;anchor=H5#H5\">",
"     \"Excitation-contraction coupling in myocardium\", section on 'Role of tropomyosin and troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Troponin assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skeletal and cardiac isoforms of troponin T and troponin I are distinct, and skeletal isoforms are not detected by the monoclonal antibody-based assays currently in use, except perhaps for troponin T in some circumstances of skeletal muscle disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This specificity for cardiac isoforms is the basis for the clinical utility of cTnT and cTnI assays. Contemporary troponin assays are quite sensitive and can detect very small amounts of myocardial necrosis (&lt;1 g). Troponin C is not used clinically because both cardiac and smooth muscle share troponin C isoforms.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ESC/ACC",
"    </span>",
"    recommended that the diagnosis of MI be based on troponin levels in excess of the 99th percentile of a reference control group. As cTnT and cTnI levels are undetectable in most normal subjects, the 99th percentile is very low. .Due to variations in assay precision and individual laboratory policies, the upper limit of normal varies between laboratories, but in all cases is above the 99th percentile. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link&amp;anchor=H4#H4\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\", section on 'Variations in assays'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Troponin release without necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prolonged ischemia, myocytes are irreversibly damaged. The cell membrane degrades, followed by the gradual release of myofibril-bound cytosolic complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/4\">",
"     4",
"    </a>",
"    ]. However, it is possible that cardiac troponins can also be released into the circulation without myocyte necrosis.",
"   </p>",
"   <p>",
"    Troponin release in the absence of necrosis may occur in conditions that produce increased myocyte membrane permeability. As an example, it is thought that myocardial depressive factors (released in the setting of sepsis and other inflammatory states) cause degradation of free troponin to lower-molecular-weight fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/5\">",
"     5",
"    </a>",
"    ]. With increased membrane permeability, those smaller troponin fragments could be released into the systemic circulation. In this setting, troponin may be elevated although myocyte necrosis may not have occurred. This hypothesis is also supported by the clinical observation that myocardial depression during sepsis is a fully reversible process in most surviving patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/6\">",
"     6",
"    </a>",
"    ]. However, direct proof of this phenomenon is lacking and it is highly controversial. Moreover, in the vast majority of settings in which circulating troponin are detected, the cause is myocyte necrosis, whether from ischemia or other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin elevations have been reported in a variety of clinical scenarios other than an acute thrombotic occlusion of the coronary artery. One approach to describing these potential causes is to consider three major categories: 1) Myocardial damage related to secondary myocardial ischemia; 2) Myocardial damage related to non-ischemic causes; 3) Myocardial injury that is multifactorial or of indeterminate cause [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Below is a list of some of the causes for the elevation of troponin in the absence of an acute coronary syndrome, each of which can be grouped according to the three categories above (",
"    <a class=\"graphic graphic_table graphicRef54910 \" href=\"UTD.htm?25/7/25724\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Notably, in some circumstances these potential categories of causes may be overlapping or impossible to discriminate completely from each other, such as in the case of patients with stable ischemic heart disease who become severely ill, tachycardic, and hypotensive with sepsis.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachy- or bradyarrhythmias, or heart block",
"     </li>",
"     <li>",
"      Critically ill patients, especially with diabetes, respiratory failure or sepsis",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy",
"     </li>",
"     <li>",
"      Coronary vasospasm",
"     </li>",
"     <li>",
"      Acute neurological disease, including stroke or subarachnoid hemorrhage",
"     </li>",
"     <li>",
"      Cardiac contusion or other trauma including surgery, ablation, pacing, implantable cardioverter-defibrillator shocks, cardioversion, endomyocardial biopsy, cardiac surgery, following interventional closure of atrial septal defects",
"     </li>",
"     <li>",
"      Rhabdomyolysis with cardiac injury",
"     </li>",
"     <li>",
"      Congestive heart failure - acute and chronic",
"     </li>",
"     <li>",
"      Pulmonary embolism, severe pulmonary hypertension",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Aortic dissection",
"     </li>",
"     <li>",
"      Aortic valve disease",
"     </li>",
"     <li>",
"      Apical ballooning syndrome - Takotsubo Cardiomyopathy",
"     </li>",
"     <li>",
"      Infiltrative diseases (ie, amyloidosis, hemochromatosis, sarcoidosis, and scleroderma)",
"     </li>",
"     <li>",
"      Inflammatory diseases (ie, myocarditis or myocardial extension of",
"      <span class=\"nowrap\">",
"       endo-/pericarditis,",
"      </span>",
"      Kawasaki disease)",
"     </li>",
"     <li>",
"      Drug toxicity or toxins (ie, adriamycin, 5-flurouracil, herceptin, snake venom)",
"     </li>",
"     <li>",
"      Burns, especially if affecting &gt;25 percent of body surface area",
"     </li>",
"     <li>",
"      Exertion",
"     </li>",
"     <li>",
"      Transplant vasculopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2007 joint",
"    <span class=\"nowrap\">",
"     ESC/ACCF/AHA/WHF",
"    </span>",
"    task force recommends that an elevated value of cardiac troponin, in the absence of clinical evidence of ischemia, should prompt a search for other causes of myocardial necrosis as listed above [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/1\">",
"     1",
"    </a>",
"    ]. We find it useful to consider whether the most likely cause is an acute cardiopulmonary condition, (such as myocarditis, pulmonary embolism, or heart failure), or a non-cardiopulmonary cause (such as sepsis or renal failure), as this consideration may be useful in directing the initial diagnostic evaluation.",
"   </p>",
"   <p>",
"    In one series of 21 patients with elevated troponin levels and a normal coronary angiogram, the following etiologies for troponin elevations were suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachycardia - 28 percent",
"     </li>",
"     <li>",
"      Pericarditis - 10 percent",
"     </li>",
"     <li>",
"      Heart failure - 5 percent",
"     </li>",
"     <li>",
"      Strenuous exercise - 10 percent",
"     </li>",
"     <li>",
"      No clear precipitating event - 47 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Elevation in the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of stored plasma samples from 3557 participants in the population-based Dallas Heart Study evaluated the prevalence of cTnT elevations in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/9\">",
"     9",
"    </a>",
"    ]. The data strongly support the concept that normal individuals have very low (in this study undetectable) levels of troponin. Values &ge;0.01",
"    <span class=\"nowrap\">",
"     microg/L,",
"    </span>",
"    which is the 99th percentile of the reference range, were seen in 0.7 percent, which is lower than one would expect from a general population as opposed to a presumably normal population.",
"   </p>",
"   <p>",
"    Troponin T elevations primarily occurred in individuals with heart failure, left ventricular hypertrophy, chronic kidney disease, or diabetes, each of which was independently associated with a cTnT elevation. These associations were seen even with minimal elevations in cTnT (0.01 to 0.029",
"    <span class=\"nowrap\">",
"     microg/L).",
"    </span>",
"    Elevations in cTnT were rare in individuals without these underlying disorders, who were more similar to a normal population.",
"   </p>",
"   <p>",
"    In summary, these observations demonstrate that a small number of troponin elevations can be due to structural heart disease in the absence of any acute process. The cTnT elevations seen in patients with renal failure may also be due to structural abnormalities and are invariably associated with pathological evidence of myocardial injury. Although some may prefer cTnI to diagnose ACS in these patients, cTnT can be used equally well by simply observing rising values [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An updated study from this same population using a high-sensitivity assay for cTnT (hs-TnT) showed an increase in the (sample-weight-adjusted) prevalence of detectable troponin to 25 percent compared with 0.7 percent using the standard assay. The prevalence of a hs-cTnT concentration of 0.014",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or above (the 99th percentile cutpoint for diagnosis of MI) was 2.0 percent.",
"   </p>",
"   <p>",
"    In the analyses based on hs-TnT, elevation of troponin remained associated with age, left ventricular hypertrophy, left ventricular systolic dysfunction, and chronic kidney disease. After adjustment for traditional risk factors, chronic kidney disease, and other biomarkers (C-reactive protein, and N-terminal pro-brain-type natriuretic peptide), hs-cTnT remained independently associated with all-cause mortality (adjusted hazard ratio, 2.8 [95% CI, 1.4-5.2] in the group greater than the 99th percentile reference limit) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Demand ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of \"demand ischemia\" refers to a mismatch between myocardial oxygen demand and supply. The term was originally applied to patients with evidence of ischemia but no CHD. Although the same pathophysiologic principle may be valid in patients with CHD, it is often more difficult to identify the predominant mechanism of ischemia in such patients. The 2007 Joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation",
"    <span class=\"nowrap\">",
"     (ESC/ACCF/AHA/WHF)",
"    </span>",
"    Task Force for the definition of myocardial infarction refers to a Type 2 myocardial infarction when the event is secondary to ischemia due to either an increased oxygen demand or a decreased supply in the absence of an acute primary coronary thrombotic event [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/1\">",
"     1",
"    </a>",
"    ]. Examples include coronary artery spasm, coronary embolism, anemia, arrhythmias, hypertension, or hypotension.",
"   </p>",
"   <p>",
"    Myocardial oxygen demand and serum troponins are increased in a number of clinical settings: sepsis, septic shock, and the systemic inflammatory response syndrome (SIRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]; hypotension or hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/14\">",
"     14",
"    </a>",
"    ]; noncardiac critically ill patients presented to the Emergency Department [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/15\">",
"     15",
"    </a>",
"    ]; and atrial fibrillation or other tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. In these settings, increased myocardial oxygen demand can be due to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Changes in cardiac loading conditions",
"     </li>",
"     <li>",
"      Increases in cardiac output to accommodate increased systemic oxygen consumption",
"     </li>",
"     <li>",
"      Myocardial depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Simultaneously, myocardial oxygen delivery may be reduced due to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced coronary perfusion, due to both tachycardia, which reduces diastolic time, during which coronary flow occurs, and reduced perfusion pressure in the setting of hypotension and increased cardiac filling pressures.",
"     </li>",
"     <li>",
"      Decreased oxygen delivery to the heart.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultimately, these forces combine to create mismatch in myocardial oxygen supply and demand, resulting in ischemia and the release of troponin into the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin elevations in patients with critical illness are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/12-15,17\">",
"     12-15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence and significance of demand ischemia in sepsis and SIRS were illustrated in a report of 20 patients treated in a medical intensive care unit (ICU) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      17 patients (85 percent) had elevated cTnI levels.",
"     </li>",
"     <li>",
"      10 of these 17 patients had no evidence of significant CHD.",
"     </li>",
"     <li>",
"      Five patients with an elevated cTnI died, all of whom had autopsies, and the coronary arteries were normal in four of these cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential causes and prognostic implications of demand ischemia were further described in a report of 58 patients, the majority of whom were admitted to an ICU for sepsis, septic shock, or SIRS [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      32 patients (55 percent) had elevated troponin levels.",
"     </li>",
"     <li>",
"      Mortality was significantly higher in patients with troponin elevations (22 versus 5 percent).",
"     </li>",
"     <li>",
"      Tumor necrosis factor-alpha, interleukin-6, and C-reactive protein levels were significantly higher in patients with elevated troponin levels.",
"     </li>",
"     <li>",
"      Significant coronary artery disease was excluded in 72 percent of troponin-positive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, troponin elevation among patients with sepsis and SIRS is common. Affected patients often have no evidence of significant CHD. In this setting, troponin elevation is associated with a worse prognosis, but it is unclear whether any cardiovascular intervention could improve outcomes. Although a causal relationship has yet to be established, inflammatory mediators in conjunction with a myocardial oxygen demand-supply mismatch are potential explanations for this phenomenon.",
"   </p>",
"   <p>",
"    Troponin elevations suggestive of demand ischemia have also been described in a broader range of critically ill patients. A 2006 review evaluated 20 observational studies involving 3278 critically ill patients in which cardiac troponin concentrations were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/17\">",
"     17",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The frequency of elevated cardiac troponin was 12 to 85 percent, with a median of 43 percent.",
"     </li>",
"     <li>",
"      In six studies in which adjusted analyses were performed, elevated cardiac troponin was associated with a significantly increased risk of death (OR, 2.5; 95 percent CI, 1.9 to 3.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardia alone has been implicated as a cause of troponin elevations in small case series. In one series of 21 patients with elevated cTnI levels and normal coronary angiograms, tachycardia was determined to be the explanation of the troponin elevation in six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/8\">",
"     8",
"    </a>",
"    ]. A second series described four patients with troponin elevations after episodes of supraventricular tachycardia (SVT), who had no evidence of CHD. These reports illustrate that myocardial troponin can be released as a consequence of tachycardia alone in the absence of myodepressive factors, inflammatory mediators, and CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponin elevation also has been described in the context of left ventricular hypertrophy (LVH). In a series of 74 consecutive patients without clinical evidence of active myocardial ischemia referred for routine echocardiography, seven of 25 patients in the tertile with the greatest LV mass had an elevated cTnI. In contrast, one patient in the intermediate range, and none of patients in the lowest tertile had an elevated troponin level [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is well recognized that LVH can lead to occult subendocardial ischemia via increased oxygen demand from increased muscle mass, coupled with decreased flow reserve due to remodeled coronary microcirculation. Similar observations have been made in the setting of aortic valve disease, in which elevated troponin level was associated with greater left ventricular wall thickness and higher pulmonary artery systolic pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coronary vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial ischemia caused by coronary vasospasm (Prinzmetal angina) can lead to troponin elevations. This was illustrated in a series of 93 patients with suspected myocardial ischemia in whom coronary angiography revealed no hemodynamically significant lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/20\">",
"     20",
"    </a>",
"    ]. Twenty-three (25 percent) had elevated levels of cTnI.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/213?source=see_link\">",
"     Ergonovine",
"    </a>",
"    provocation testing showed evidence of coronary vasospasm in 41 patients, and in 17 of the 23 patients with cTnI elevations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both elevated cardiac troponin levels and ischemic ECG changes have been described in the setting of acute stroke or intracranial hemorrhage. In one series of 149 patients with symptoms of acute stroke, 27 percent were found to have elevated serum cTnI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link\">",
"     \"Cardiac complications of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevations in cTnI have also been noted in two case series of patients with subarachnoid hemorrhage (SAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In these reports, cTnI elevations correlated with both the severity of neurologic injury and cardiovascular abnormalities including left ventricular dysfunction, pulmonary edema, and hypotension requiring pressors. In one of the studies, elevations in cTnI also predicted a higher likelihood of in-hospital death or severe disability at discharge, although this relationship was no longer significant at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H24#H24\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Cardiac abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most likely explanation of troponin elevation and myocardial damage in this setting is an imbalance of the autonomic nervous system, with resulting excess of sympathetic activity and increased catecholamine effect on the myocardial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of troponin elevation in these reports is often less than that seen with acute myocardial infarction due to coronary artery occlusion. Thus, it is not clear to what extent the LV dysfunction and hemodynamic compromise reported in these case series were due to acute myocardial injury in the setting of the stroke, or reflect new myocardial and hemodynamic stress in patients with underlying cardiovascular disease.",
"   </p>",
"   <p>",
"    In addition, since follow-up echocardiograms were not routinely obtained, it is not known how many of these patients may have had improvement in left ventricular function after recovering from the acute stroke. Reversible LV dysfunction in the setting of acute noncardiac illness is an increasingly reported phenomenon, and autonomic imbalance with catecholamine excess is proposed to play a role in both stroke-related myocardial injury and stress-induced cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Direct myocardial damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin elevation can occur in the setting of myocardial injury by traumatic or inflammatory processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and significance of cTnI elevations following blunt thoracic trauma were illustrated in a report of 333 patients, in whom serial ECGs and cTnI values were followed over eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/25\">",
"     25",
"    </a>",
"    ]. Elevation in cTnI occurred in 145 patients (44 percent); 44 patients (13 percent) had evidence of clinically significant blunt cardiac injury, defined by hypotension, arrhythmias, anatomic abnormalities, or depressed cardiac index, 32 of whom had cTnI elevations. Thus, a degree of direct cardiac injury, as evidenced by cTnI elevations, is common after blunt chest trauma, although only a minority of patients with troponin elevations in this setting develop significant clinical complications attributable to cardiac injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Additional causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other clinical conditions in which direct myocardial injury may occur have been associated with elevated troponin levels. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Implantable cardioverter-defibrillator shocks [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infiltrative disorders such as amyloidosis; it has been postulated that extracellular amyloid deposition may lead to myocyte compression injury, leading to myocardial damage and troponin release [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High-dose chemotherapy; troponin levels have been suggested as a method for detecting cardiotoxicity and predicting the development of future left ventricular dysfunction in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory disorders including acute pericarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/29\">",
"       29",
"      </a>",
"      ] and myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link\">",
"       \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immune response after heart transplantation. Chronically elevated troponin levels after cardiac transplantation may be associated with a poorer prognosis. In a prospective cohort study of 110 consecutive patients after cardiac transplantation, troponin levels remained persistently elevated in 51 percent of patients and were associated with more fibrin deposition in the microvasculature and among myocytes, as well as a significant increase in the risk for coronary artery disease and graft failure [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure can lead to the release of cardiac troponin via two related mechanisms, myocardial strain and myocyte death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Myocardial strain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume and pressure overload of both the right and left ventricle can produce excessive wall tension or \"myocardial strain,\" with resulting myofibrillar damage [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/19\">",
"     19",
"    </a>",
"    ]. Support for a connection between myocardial strain and elevated troponin levels comes from several lines of evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a close correlation between troponin levels and B-type natriuretic peptide (BNP), and BNP is itself a marker of right and left ventricular wall strain [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Troponin degradation has been demonstrated with increased preload, independent of myocardial ischemia, in isolated rat hearts [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased myocardial wall stress may lead to decreased subendocardial perfusion, with resulting troponin elevation and decline in left ventricular systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Troponin elevation in normal persons after ultra-endurance exercise have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. This may be related to an increase in myocardial strain during exercise, although catecholamine-induced vasospasm has also been invoked as an explanation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Myocyte death",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, in vitro experiments with myocytes established a link between myocardial wall stretch and programmed cell death, which may also contribute to troponin elevations in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/37\">",
"     37",
"    </a>",
"    ]. Progressive myocyte loss is now thought to play a prominent role in the progression of cardiac dysfunction and may explain the ominous prognosis of patients with heart failure and elevated troponin levels. Several factors may contribute to myocyte death, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activation of the renin-angiotensin system",
"     </li>",
"     <li>",
"      Sympathetic stimulation",
"     </li>",
"     <li>",
"      Inflammatory mediators",
"     </li>",
"     <li>",
"      Integrin stimulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin elevations tend to be associated with advanced heart failure and an adverse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/34\">",
"     34",
"    </a>",
"    ]. The clinical evidence supporting this association is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H32#H32\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponin elevations are also described in a variety of pulmonary diseases, usually associated with significant right heart strain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum troponins are elevated in 30 to 50 percent of patients with a moderate to large pulmonary embolism. The presumed mechanism is acute right heart overload and elevated levels are associated with a significant increase in mortality. The troponin elevations usually resolve within 40 hours with pulmonary embolism in contrast to the more prolonged elevation with acute myocardial injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'Laboratory'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of cTnT were elevated in 8 of 56 patients (14 percent) with chronic pulmonary hypertension in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/38\">",
"     38",
"    </a>",
"    ]. cTnT elevations were associated with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher heart rates",
"     </li>",
"     <li>",
"      Lower mixed venous oxygen saturation",
"     </li>",
"     <li>",
"      Higher levels of B-type natriuretic peptide",
"     </li>",
"     <li>",
"      Significantly lower two year survival (29 versus 81 percent with normal cTnT levels)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exacerbation of chronic obstructive pulmonary disease can also increase troponin levels and has been identified as an independent predictor of in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent elevation of cardiac troponin is frequently observed among patients with end-stage renal disease; cTnI is the preferred test in this setting. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=see_link&amp;anchor=H2#H2\">",
"     \"Serum cardiac enzymes in patients with renal failure\", section on 'Troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe thermal injury is associated with cardiac contractile dysfunction and elevated cardiac troponin. Elevation of cardiac troponin is demonstrated among patients who have sustained &gt;25 percent (total body surface area) of thermal injury. The rise in cardiac troponin appears to be related to the extent of burns rather than patient's age, pre-existing medical conditions or the administration of resuscitation fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of elevated cardiac troponin and myocarditis among patients with Kawasaki disease (KD) is not clear. One group suggested that among children with Kawasaki disease there is a significant increase in the cardiac troponin, which would indicate acute myocarditis and myocardial cell injury in the early stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/41\">",
"     41",
"    </a>",
"    ]. On the contrary, another study did not demonstrate significant elevation in cardiac troponin among KD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardioversion and defibrillation can lead to mild but significant rise in cardiac troponin levels. This rise is more pronounced among patients with relatively large left ventricular end diastolic dimensions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2537/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Troponin is a highly sensitive biomarker that aids in the detection of myocardial cell damage, which is often, but not always, due to thrombotic obstruction of a coronary artery. Thus, while troponin may be useful to \"rule out\" a non-ST elevation MI (NSTEMI), the clinician must recognize the limitations of using troponin to \"rule in\" myocardial infarction in patients with low clinical likelihood of an acute coronary syndrome (ACS). While troponin is highly specific for myocardial injury, it is not specific for ACS as the cause. As a result, if troponin testing is applied indiscriminately in broad populations with a low pretest probability of thrombotic disease, the positive predictive value for ACS is greatly diminished.",
"     </li>",
"     <li>",
"      Troponin elevation in the absence of an ACS still retains significant prognostic value, and screening may be justified on this basis. Troponin elevations in a variety of settings predict worse short- and long-term survival. The reasons for this increase in mortality are currently poorly understood, but may be related to several factors, including myocardial necrosis with myocyte loss, or underlying quiescent coronary artery disease. Alternatively, increased troponin levels may reflect a more fulminant disease process. Regardless of the reason for poorer prognosis, patients with troponin elevation require appropriate diagnostic evaluation and therapy aimed at the underlying disorder. In addition, we believe that evaluation for structural heart disease with echocardiography or cardiac magnetic resonance imaging is warranted in selected cases where there is reasonable suspicion for a cardiopulmonary etiology, so as to guide preventive care and long term monitoring (eg, significant left ventricular dysfunction or valvular heart disease).",
"     </li>",
"     <li>",
"      Determining whether a troponin elevation is due to an ACS can be difficult. Factors that suggest CHD and an ACS include ischemic electrocardiographic changes, chest pain, wall-motion abnormalities on echocardiography, and the presence of atherosclerotic risk factors. If present, these should guide the use of further cardiovascular evaluation, including early risk stratification.",
"     </li>",
"     <li>",
"      Patients with a low pretest probability of coronary heart disease are unlikely to derive benefit from a treatment strategy aimed at coronary thrombosis (eg, aggressive antiplatelet therapy, coronary angiography, and revascularization). In such patients, the main goal is to identify the underlying cause of the troponin elevation. This frequently becomes evident after a thorough history and physical examination, which can identify conditions such as myocarditis, pericarditis, cardiac contusion, sepsis, pulmonary embolism, and heart failure. Therapy in these circumstances should target the underlying cause.",
"     </li>",
"     <li>",
"      There are currently no data from randomized trials evaluating the efficacy of therapies aimed at reducing risk in patients with troponin elevations in the majority of settings absent of an ACS. As a result, we do not generally treat most patients with non-thrombotic troponin elevation with aggressive antithrombotic and antiplatelet agents. However, there are some settings, such as pulmonary embolism and administration of cardiotoxic chemotherapeutics, where there is evidence that suggests troponin is useful for clinical decision making.",
"     </li>",
"     <li>",
"      No current data support an early invasive mechanical revascularization strategy in patients in whom the suspicion of thrombotic coronary heart disease is low. We do recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , unless it is contraindicated, as it appears to be relatively safe in most clinical circumstances.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/1\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/3\">",
"      Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011; 58:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/4\">",
"      Higgins JP, Higgins JA. Elevation of cardiac troponin I indicates more than myocardial ischemia. Clin Invest Med 2003; 26:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/5\">",
"      Wu AH. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression? Intensive Care Med 2001; 27:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/6\">",
"      Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/7\">",
"      Thygesen K, Mair J, Katus H, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010; 31:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/8\">",
"      Bakshi TK, Choo MK, Edwards CC, et al. Causes of elevated troponin I with a normal coronary angiogram. Intern Med J 2002; 32:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/9\">",
"      Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/10\">",
"      Ie EH, Klootwijk PJ, Weimar W, Zietse R. Significance of acute versus chronic troponin T elevation in dialysis patients. Nephron Clin Pract 2004; 98:c87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/11\">",
"      de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/12\">",
"      Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/13\">",
"      Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/14\">",
"      Arlati S, Brenna S, Prencipe L, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med 2000; 26:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/15\">",
"      Wright RS, Williams BA, Cramner H, et al. Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol 2002; 90:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/16\">",
"      Zellweger MJ, Schaer BA, Cron TA, et al. Elevated troponin levels in absence of coronary artery disease after supraventricular tachycardia. Swiss Med Wkly 2003; 133:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/17\">",
"      Lim W, Qushmaq I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med 2006; 166:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/18\">",
"      Hamwi SM, Sharma AK, Weissman NJ, et al. Troponin-I elevation in patients with increased left ventricular mass. Am J Cardiol 2003; 92:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/19\">",
"      Nunes JP, Mota Garcia JM, Farinha RM, et al. Cardiac troponin I in aortic valve disease. Int J Cardiol 2003; 89:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/20\">",
"      Wang CH, Kuo LT, Hung MJ, Cherng WJ. Coronary vasospasm as a possible cause of elevated cardiac troponin I in patients with acute coronary syndrome and insignificant coronary artery disease. Am Heart J 2002; 144:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/21\">",
"      Tro&oslash;yen M, Indredavik B, Rossvoll O, Sl&oslash;rdahl SA. [Myocardial injury in acute stroke assessed by troponin I]. Tidsskr Nor Laegeforen 2001; 121:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/22\">",
"      Tung P, Kopelnik A, Banki N, et al. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke 2004; 35:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/23\">",
"      Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation 2005; 112:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/24\">",
"      Homma S, Grahame-Clarke C. Editorial comment--myocardial damage in patients with subarachnoid hemorrhage. Stroke 2004; 35:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/25\">",
"      Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of clinically significant blunt cardiac injury. J Trauma 2003; 54:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/26\">",
"      Hasdemir C, Shah N, Rao AP, et al. Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks. J Cardiovasc Electrophysiol 2002; 13:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/27\">",
"      Cantwell RV, Aviles RJ, Bjornsson J, et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol 2002; 25:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/28\">",
"      Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/29\">",
"      Brandt RR, Filzmaier K, Hanrath P. Circulating cardiac troponin I in acute pericarditis. Am J Cardiol 2001; 87:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/30\">",
"      Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997; 95:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/31\">",
"      Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000; 284:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/32\">",
"      Logeart D, Beyne P, Cusson C, et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J 2001; 141:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/33\">",
"      Feng J, Schaus BJ, Fallavollita JA, et al. Preload induces troponin I degradation independently of myocardial ischemia. Circulation 2001; 103:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/34\">",
"      Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/35\">",
"      Rifai N, Douglas PS, O'Toole M, et al. Cardiac troponin T and I, echocardiographic [correction of electrocardiographic] wall motion analyses, and ejection fractions in athletes participating in the Hawaii Ironman Triathlon. Am J Cardiol 1999; 83:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/36\">",
"      Neumayr G, Gaenzer H, Pfister R, et al. Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise. Am J Cardiol 2001; 87:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/37\">",
"      Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995; 96:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/38\">",
"      Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/39\">",
"      Baillard C, Boussarsar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2003; 29:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/40\">",
"      Murphy JT, Horton JW, Purdue GF, Hunt JL. Evaluation of troponin-I as an indicator of cardiac dysfunction after thermal injury. J Trauma 1998; 45:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/41\">",
"      Kim M, Kim K. Elevation of cardiac troponin I in the acute stage of Kawasaki disease. Pediatr Cardiol 1999; 20:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/42\">",
"      Checchia PA, Borensztajn J, Shulman ST. Circulating cardiac troponin I levels in Kawasaki disease. Pediatr Cardiol 2001; 22:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2537/abstract/43\">",
"      Piechota W, Gielerak G, Ryczek R, et al. Cardiac troponin I after external electrical cardioversion for atrial fibrillation as a marker of myocardial injury--a preliminary report. Kardiol Pol 2007; 65:664.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1469 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2537=[""].join("\n");
var outline_f2_30_2537=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CARDIAC TROPONINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Troponin assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Troponin release without necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Elevation in the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Demand ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Critical illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coronary vasospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Direct myocardial damage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Additional causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Myocardial strain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Myocyte death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Burns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cardioversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/7/25724\" title=\"table 1\">",
"      Non-ACS causes of elevated troponin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2538="Nonpharmacologic therapy of osteoarthritis";
var content_f2_30_2538=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonpharmacologic therapy of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/30/2538/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/30/2538/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of management of patients with osteoarthritis (OA) are to control pain and swelling, to minimize disability, to improve the quality of life, to prevent progression of the process, and to educate the patient about his or her role in the management team. Management should be individualized to the patient's expectations, level of function and activity, to the joints involved and the severity of the patient's disease, to occupational and vocational needs, and to the nature of any coexisting medical problems. Subjective complaints and objective findings may guide the clinician in designing appropriate therapeutic goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An essential component in the development of a therapeutic plan is the correct attribution of signs and symptoms at the target site. Pain and other symptoms of OA can be confused with soft tissue processes such as bursitis at periarticular sites; in addition, pain in a particular area may be referred from OA at other site or may be due to a nonarticular process.",
"   </p>",
"   <p>",
"    The American College of Rheumatology (ACR) has developed classification criteria for OA of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/1\">",
"     1",
"    </a>",
"    ] and knee [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/2\">",
"     2",
"    </a>",
"    ] in order to assist the clinician in identifying patients with symptomatic OA of these areas. Classification criteria for other areas have not been developed, but a rheumatologist can be helpful in difficult situations.",
"   </p>",
"   <p>",
"    This topic review will discuss the major nonpharmacologic modalities used in the treatment of OA, including weight loss, rest, physical therapy, and exercise. The roles of pharmacologic and surgical therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The generalized therapeutic approach to patients with inflammatory or noninflammatory OA is outlined (",
"    <a class=\"graphic graphic_algorithm graphicRef75993 \" href=\"UTD.htm?25/25/26015\">",
"     algorithm 1",
"    </a>",
"    ). North American and European guidelines for the management of specific sites of OA have also been developed for the hand, hip, and knee (",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/guidelines/PDFs/ACR_OA_Guidelines_FINAL.pdf\">",
"     file://www.rheumatology.org/practice/clinical/guidelines/PDFs/ACR_OA_Guidelines_FINAL.pdf#toolbar=1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in these guidelines are required for certain sites of involvement; as an example, not all joints are amenable to arthroscopic irrigation or synovectomy, and arthroplasty cannot be performed on many joints.",
"   </p>",
"   <p>",
"    Both inflammatory and noninflammatory OA can be polyarticular, pauciarticular, or monoarticular. There are, however, differences in symptoms and physical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with noninflammatory OA generally have pain and disability-related complaints as their only symptoms. Physical findings in affected joints include tenderness, bony prominence, and crepitus.",
"     </li>",
"     <li>",
"      Patients with inflammatory OA complain of articular swelling, morning stiffness lasting for more than 30 minutes, and night pain. Signs of inflammation include joint effusion on examination or radiography, warmth on palpation of the joint, and synovitis on arthroscopic examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     WEIGHT LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies suggest that obesity is strongly associated with the development of OA. One study, for example, noted an increased risk of developing OA of the knee in patients with high body mass indices (1.5 and 2.1 for men and women, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/6\">",
"     6",
"    </a>",
"    ]. In a follow-up study using the same population, the risk of developing OA was reduced following weight loss; a ten-pound weight loss over 10 years decreased the odds for developing knee OA by 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/7\">",
"     7",
"    </a>",
"    ]. The relation between the degree of weight loss and the reduced incidence of OA was linear, suggesting that even modest weight loss may be beneficial.",
"   </p>",
"   <p>",
"    In addition to reducing the risk of progression of OA, weight loss of even modest degree, may produce improvement in joint pain and function. As an example, in a prospective study 316 overweight people with symptomatic and radiographic OA of the knees were randomly assigned to one of four groups: diet alone, exercise alone, diet and exercise, or education in healthy living [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/8\">",
"     8",
"    </a>",
"    ]. The combination of diet and exercise was the most effective and was associated with decreased knee pain and improved self-reported and measured function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis is associated with pain and other symptoms after prolonged use; these symptoms are improved with rest. Resting the affected joint may alleviate pain; however, prolonged rest may lead to muscle atrophy and decreased joint mobility. Therefore, rest is recommended for only short periods of time, typically 12 to 24 hours for acute pain and inflammatory signs, after which active and passive joint motion and exercises should resume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHYSICAL THERAPY AND ORTHOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence and general belief that physical therapy and exercise improve clinical outcome in OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/9\">",
"     9",
"    </a>",
"    ]. While some physicians may have the experience and training required to specify the type of therapy, the frequency, and the duration, others may wish to defer these decisions to a specialist in rehabilitation medicine or to the therapist. Thus, a prescription that includes the diagnosis and requests evaluation and treatment should suffice. A general description of any desired orthotics or assistive devices may also be included.",
"   </p>",
"   <p>",
"    By improving flexibility and strengthening muscles supporting the affected joints, patients improve functional outcome and pain scores. These interventions are believed to \"unload\" the joints by improving mechanical forces during use. Data supporting the role of physical therapy modalities continues to accumulate. One report, for example, examined the distribution of walking forces by muscular structures in patients with knee pain. These patients had abnormal joint loading at heel strike, leading to a 30 percent increase in force [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/10\">",
"     10",
"    </a>",
"    ]. This abnormality may reflect the inability of musculoskeletal structures to absorb forces due to injury.",
"   </p>",
"   <p>",
"    An older study in normal subjects supports a role for muscular elements in force absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/11\">",
"     11",
"    </a>",
"    ]. Falls from low heights were found to generate the same maximal foot force as those from higher heights. This seeming paradox was accounted for by the smooth prolonged force curve generated when the subject had time to anticipate the fall and control the deceleration with lower extremity muscles. Small height falls produced jarring impacts, since the brunt of the force was absorbed by skeletal structures. Larger heights, despite having more momentum, were less traumatic, since the skeletal muscles absorbed the impact and deceleration occurred over a longer time period.",
"   </p>",
"   <p>",
"    Methods that simulate this process may aid in preventing excessive joint loads and pain. Such techniques include padded shoes and quadriceps training. Padded, protective shoes can decrease the joint load on impact. One report measured heel strike forces during normal gait; the use of compliant, soft heels halved the amplitude of transient forces on heel strike [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/12\">",
"     12",
"    </a>",
"    ]. Small, unblinded studies suggest that a similar benefit may be achieved with the use of visco-elastic inserts or wedged insoles [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Insoles appear to reduce loading on the medial knee joint surface by shifting of the calcaneus to a valgus position in the subtalar region and by altering the axis of the lower limb to a more upright position [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/14\">",
"     14",
"    </a>",
"    ]. However, in a double-blind study that compared five-degree wedged insoles to neutral insoles in patients with OA of the knee, no clinically or statistically significant differences were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/16\">",
"     16",
"    </a>",
"    ]. One possible explanation suggested for the lack of benefit in the latter trial was the absence of any constraint of ankle mobility.",
"   </p>",
"   <p>",
"    Although further study is necessary, a trial of soft, elastic heeled sports shoes or the use of insoles is appropriate for patients with knee OA. Other methods of unloading an osteoarthritic joint include canes and walkers. These assistive devices can reduce joint forces at the hip by as much as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of a combination of manual physical therapy and exercise is uncertain as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One controlled clinical trial randomized 83 patients with osteoarthritis of the knee to receive either manual therapy combined with a standardized knee exercise program or to subtherapeutic (ie, placebo) ultrasonography, each for a total of 4 weeks administered 2 times per week [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/18\">",
"       18",
"      </a>",
"      ]. Active therapy resulted in a statistically significant improvement in 6 minute walking distance and the sum of function, pain, and stiffness scores, both at 8 weeks (average difference of 170 meters) and one year. In addition, fewer patients undergoing manual physical therapy and exercise required surgical intervention (5 versus 20 percent for the placebo group).",
"     </li>",
"     <li>",
"      A second study of 140 people with OA of the knee who were randomly assigned to a multimodal physical therapy program or to sham ultrasound and placebo gel applications found similar improvements in knee pain and patient reported global status in both groups [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A program of muscle stretching and joint manipulation by a therapist trained in \"manual therapy\" may be more beneficial for patients with osteoarthritis of the hip than exercise programs that focus on muscle strengthening, endurance training, and improved coordination. This was illustrated in a study that randomly assigned 109 patients to \"manual therapy\" or an individualized exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/20\">",
"     20",
"    </a>",
"    ]. After five weeks, a significantly greater proportion of those who received manual therapy had better self-reported outcomes than the exercise group (81 versus 50 percent improved, respectively).",
"   </p>",
"   <p>",
"    As will be described further below, exercise produces a variety of benefits in the patient with OA. Supervised rather than home exercise programs are more likely to be maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Braces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Braces and splints may be useful for symptomatic relief for those with OA of certain joints. As an example, valgus bracing of the knee reduced pain can improve function in patients with osteoarthritis of the knee that predominantly affected the medial compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/22\">",
"     22",
"    </a>",
"    ]. Our experience suggests that some patients may get symptomatic relief from use of a simple sleeve elastic knee brace, a less cumbersome and less costly alternative. Splints made of thermoplastic may be useful for OA of the carpometacarpal and interphalangeal joints of the thumb [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patellofemoral syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain occurring in the patellofemoral syndrome originates from patellar malalignment, which increases forces to the lateral knee compartment. The value of bracing and therapeutic taping of the knee for this disorder is controversial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=see_link\">",
"     \"Patellofemoral pain syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Knee taping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of therapeutic knee taping for pain in the patellofemoral syndrome is controversial, it may be useful for other patients with OA of the knee. This was illustrated in a trial of 87 patients who were randomly assigned to receive therapeutic taping, control taping, or no taping [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/24\">",
"     24",
"    </a>",
"    ]. Therapeutic taping consisted of weekly application of strapping tape over a base of hypoallergenic tape in a transverse, anterior suprapatellar location to allow \"medial glide, medial tilt, and anteroposterior tilt to the patella\" and a second, circumferential application of tape to cover the infrapatellar or anserine bursa, depending upon the site of maximal tenderness.",
"   </p>",
"   <p>",
"    After three weeks of treatment, patients who received taping were significantly more likely to experience improvement in knee pain than the control-tape and no-tape controls (73, 49, and 10 percent, respectively). Skin irritation, described as minor, developed in 28 percent of those receiving therapeutic-taping, but did not lead to withdrawal in any of the subjects.",
"   </p>",
"   <p>",
"    Additional study is needed before the appropriate place for knee taping in the treatment of OA can be determined. However, it is inexpensive, has few adverse effects, and appears promising based on the limited data available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between exercise and arthritis has been the subject of considerable controversy. However, studies support an appropriate exercise program as an integral part of the optimal, multidisciplinary management of OA. Patients with OA frequently have deficiencies in gait, strength, flexibility, aerobic power, and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Several small studies suggested that these deficits could be safely reversed with a variety of exercise regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/27,28\">",
"     27,28",
"    </a>",
"    ] or even electrical muscle stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/29\">",
"     29",
"    </a>",
"    ]. This issue has been better addressed in two large, randomized trials of the impact of exercise on the disability associated with OA.",
"   </p>",
"   <p>",
"    In one study, 102 patients with documented OA of one or both knees were randomized to receive either a combined program of supervised fitness walking and education or routine medical care and telephone contact [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/30\">",
"     30",
"    </a>",
"    ]. The lack of an equal co-intervention was a notable limitation of this trial. Nevertheless, the following benefits were noted at eight weeks in the exercise group compared to those receiving usual care:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 70 m (18.4 percent) increase in walking distance versus a 17 m decrease",
"     </li>",
"     <li>",
"      A 39 percent improvement in the physical activity functional status and a 27 percent decrease in arthritis pain; no significant change occurred in the usual care group",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Fitness Arthritis and Seniors Trial (FAST) compared the impact of 18 months of aerobic exercise, resistance exercise, or a health education program on several measures of disability, physical performance, and pain in elderly subjects with OA of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/31\">",
"     31",
"    </a>",
"    ]. The two exercise groups showed only modest improvement compared to the education group with regard to each of the outcome variables.",
"   </p>",
"   <p>",
"    The effect of the exercise interventions in the FAST was somewhat disappointing in its magnitude. The results were limited by the advanced age and disease of its subjects, and by the selection of low-intensity and low-cost exercises, which may have increased safety and compliance at the expense of improvement in outcome. The aerobic and resistance exercises were conducted with very few injuries, despite the use of rather high-risk exercises (including upright rows and military presses) in a high-risk group of frail elderly patients.",
"   </p>",
"   <p>",
"    A systematic review of randomized clinical trials, which investigated the effectiveness of exercise therapy for OA of the hip or knee, was published in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/32\">",
"     32",
"    </a>",
"    ], meta-analyses of randomized trials focused on OA of the knee, appeared in 2006 and 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The authors of the former study concluded that, although firm conclusions could not be obtained because of the small number of well-designed studies, there is evidence of modest benefits from exercise. The authors of the meta-analyses concluded that exercise regimens for patients with OA of the knee led to improved physical health and an at least short term beneficial effect on OA.",
"   </p>",
"   <p>",
"    A panel of the American Geriatrics Society, which supports exercise for older persons with osteoarthritis, released guidelines for exercise prescribing in such individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors must be considered in creating an individualized exercise program for a patient with OA. These include the severity and specific manifestations of the patient's disease and the frequent presence of severe deconditioning, due to the inactivity imposed by the arthritis. The last problem can also put the patient at increased risk for cardiovascular disease. Such patients must be identified and subjected to appropriate exercise testing prior to engaging in aggressive exercise programs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"     \"Weight-resistance training in patients with osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with moderate to severe OA may not have as much symptomatic benefit from exercise as those with mild disease, particularly if a relatively high intensity aerobic exercise program is employed. This was illustrated in a study that randomly assigned middle aged adults with symptomatic and radiographically apparent (grade III of IV) OA of the knee to aerobic exercise (one hour twice weekly) with a goal heart rate of 60 percent of the maximum predicted for age or to no intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/36\">",
"     36",
"    </a>",
"    ]. After six weeks there were no significant differences between groups in knee pain or function. Self-reported quality of life was significantly better in those who exercised and this difference persisted for up to six months, at which time observations were ended.",
"   </p>",
"   <p>",
"    The goals of exercise programs in OA include reduction in pain and functional impairment, protection of both involved and at-risk joints, and prevention of disability related to inactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Symptomatic relief",
"    </span>",
"    &nbsp;&mdash;&nbsp;Range of motion and strengthening exercises can reduce pain and increase mobility in patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/21,38,39\">",
"     21,38,39",
"    </a>",
"    ]. The following assessments should be made prior to beginning an exercise program: passive and active range of motion, gait, stair climbing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chair stands [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/37\">",
"     37",
"    </a>",
"    ]. These evaluations should target muscle groups that appear weak. An example of the utility of this approach is the beneficial effect of strengthening the quadriceps muscles on pain and function in patients with OA of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/21,30,40\">",
"     21,30,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tai Chi exercises specifically designed for patients with arthritis may also offer some symptomatic relief [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. One controlled trial was limited by the withdrawal of 43 percent of patients and the analysis of only those who completed 12 weeks of the Tai Chi regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/41\">",
"     41",
"    </a>",
"    ]. The other enrolled 40 subjects with radiographically confirmed knee OA, and randomly assigned them to either a 12 week program of Tai Chi instruction or 12 weeks of nutrition education and stretching exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/42\">",
"     42",
"    </a>",
"    ]. Both groups experienced a decrease in pain scores, from a mean WOMAC pain score of about 220 at baseline to a mean of about 70 and 150 (between group difference 119 [95% CI 184-54]). Secondary measures including physical function, physician and patient overall assessments, and joint stiffness all improved more in the Tai Chi group. Neither group had any significant weight loss during the study. One patient in each group had a new diagnosis of cancer and one in the Tai Chi group had an increase in knee pain that required modification of the exercises, after which she was able to continue and completed the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Joint protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercises that cause low load effects such as swimming, bicycling, walking, or Tai Chi are helpful in developing muscular strength while protecting joints [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/43\">",
"     43",
"    </a>",
"    ]. A cardiovascular warm-up followed by stretching is recommended prior to exercising to promote circulation and to limit stress across joints. Patients should avoid excessive stair climbing, which increases loading on the medial or weight-bearing aspect of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/44\">",
"     44",
"    </a>",
"    ]. Experts differ regarding the safety of running, although studies have generally failed to show that running increases the risk of knee osteoarthritis. The evidence is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=see_link\">",
"     \"Joint protection program for the lower limb\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H24287198#H24287198\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Knee OA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Joint protection can also be achieved by applying splints for temporary or extended joint immobilization. A significant benefit is the reduction of pain and inflammation, thereby ameliorating symptoms prior to the initiation of range of motion and muscle strengthening exercises. Many splints can be worn throughout the day and night without significant impediment. In addition, weight loss may be helpful (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Weight loss'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Disability prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;People who exercise regularly are healthier and live longer than people who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/45\">",
"     45",
"    </a>",
"    ]. The exercise does not need to be intense in order to improve health and avoid disability [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/46\">",
"     46",
"    </a>",
"    ]. Among the benefits that can be achieved with exercise are improvement in joint pain and mobility, reversal of muscular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/47\">",
"     47",
"    </a>",
"    ], and increased bone mineral density which reduces the risk of osteoporotic fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"    </a>",
"    .) One potential problem is that increased bone mineral density could increase the load upon weight-bearing joints, thereby enhancing the risk of OA.",
"   </p>",
"   <p>",
"    In addition to the benefits for OA, exercise has other benefits for overall health. These include improvements in cardiovascular performance, which decreases the risk of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/50\">",
"     50",
"    </a>",
"    ], and in psychosocial health, (eg, relief of symptoms of depression) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial assessment of the following factors provides the basis for designing details of exercise regimens for OA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"     \"Weight-resistance training in patients with osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence of joint inflammation",
"     </li>",
"     <li>",
"      The pattern of joint involvement",
"     </li>",
"     <li>",
"      The location and degree of muscle atrophy, loss of strength, and limitation of range of motion",
"     </li>",
"     <li>",
"      Comorbid medical conditions that may preclude exercise",
"     </li>",
"     <li>",
"      Any diminution in aerobic capacity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All programs include range of motion and isometric strengthening exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/37\">",
"     37",
"    </a>",
"    ]. For patients with active joint inflammation, advanced disease, or profound functional impairment, these interventions may be the highest level of exercise that can initially be safely achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients with less severe or more quiescent disease may progress sequentially through isotonic strengthening, aerobic exercises, and, ultimately, to recreational exercise.",
"   </p>",
"   <p>",
"    Low impact exercises to avoid excessive joint loading are preferable for patients with OA. Thus, lower extremity exercises should consist of closed chain exercises in which the feet are firmly placed on a contact surface to avoid excessive joint torsion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Aquatic exercises are of particular benefit for those with severe arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked deconditioning. The buoyancy provided by water leads to decreases in joint compression and allows exercise with relative freedom from the constraints imposed by body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Separate guidelines are available for the patient that can enhance both the safety and compliance with an exercise program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=see_link\">",
"     \"Patient guidelines for weight-resistance training in osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with exercise programs varies dramatically according to the regimen selected and the setting. Compliance can be maximized through several techniques, including simplifying regimens, setting attainable goals, educating patients to the importance and benefits of exercise, providing social interaction (with exercise groups, physical therapists or personal trainers), and providing regular follow-up to adjust the regimen according to feedback as to its initial efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/52,57\">",
"     52,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5629885\">",
"     'Self-management programs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exercise in supervised settings is typically associated with better compliance than unsupervised, home-based programs, thereby increasing the likelihood of prolonged benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/21,55\">",
"     21,55",
"    </a>",
"    ]. One study compared home exercises and hospital-based physical therapy in patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/21\">",
"     21",
"    </a>",
"    ]. Both groups showed an equivalent benefit with diminished pain, improved function, and increased strength. These improvements were retained in patients who continued to exercise, but not in those who were not compliant. With adequate compliance, however, physical therapy or exercise performed at home is as effective, less expensive, and more convenient than supervised programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aerobic versus resistance (strengthening) exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Is aerobic or resistance training, or a combination of the two, most beneficial in terms of reducing arthritis-related symptoms and disability? This question was addressed in a 2005 systematic review that included 13 randomized and controlled trials of exercise for patients with osteoarthritis of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/58\">",
"     58",
"    </a>",
"    ]. Estimates based upon pooled data suggested a moderate effect of each intervention on pain and self-reported disability (effect size for pain of 0.52 versus 0.32, and for disability 0.46 versus 0.32, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unanswered questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many research issues regarding the use of exercise as treatment for OA remain unanswered. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the optimal amount of exercise?",
"     </li>",
"     <li>",
"      Can exercise prevent the development of OA in those at risk or slow the rate of progression of OA in those already afflicted?",
"     </li>",
"     <li>",
"      What is the role of exercise directed at non-weight bearing osteoarthritic joints? It has not been established whether exercise confers systemic benefits that reduce symptoms and disability in joints distant from the focus of activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of diet in the treatment of OA remains unclear. Current research into diet as an independent factor is focused on the merits of antioxidants and vitamin D.",
"   </p>",
"   <p>",
"    One report, for example, utilized the Framingham data base to analyze the relationship of antioxidant nutrients to the development and progression of OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/59\">",
"     59",
"    </a>",
"    ]. Despite loss of nearly one-third of the cohort who had completed the questionnaires, the analyzed data strongly suggested a relationship between vitamin C intake and progression of OA; the risk of progression was reduced three-fold in patients with mean vitamin C intakes above 152 mg per day. Vitamin E and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"     beta-carotene",
"    </a>",
"    may also reduce the risk of progression, but the data on these nutrients were less consistent. In comparison, intake of these three nutrients did not affect the rate of development of OA.",
"   </p>",
"   <p>",
"    A follow-up analysis of the Framingham data suggested that the risk of OA progression increased three-fold in patients with low vitamin D intake [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/60\">",
"     60",
"    </a>",
"    ]. As with the antioxidants, however, low intake and serum levels of vitamin D did not increase the risk for developing OA.",
"   </p>",
"   <p>",
"    Data from observational studies must be interpreted with caution and confirmed in prospective trials. The efficacy of vitamin E was directly assessed in a randomized placebo-controlled study of 77 patients with OA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/61\">",
"     61",
"    </a>",
"    ]. In contrast to the observational data, the administration of vitamin E (500",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    for six months did not provide pain relief or prevent radiographic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, vitamin D supplementation is indicated in patients at high risk for osteoporosis, such as postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) No recommendations can be made regarding vitamin C and vitamin E.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HEAT AND COLD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat and cold modalities have been used for many years in the treatment of OA despite the paucity of adequate controlled, randomized clinical studies. Moist superficial heat can raise the threshold for pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/62\">",
"     62",
"    </a>",
"    ], produce analgesia by acting on free nerve endings [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/63\">",
"     63",
"    </a>",
"    ], and decrease muscle spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heat modalities include heat packs, heating pads, and paraffin wax. Caution must be taken with these techniques to avoid burns. Hot water bottles should be filled with warm but not boiling water. Timers should be used with heating pads; application of the heating pad should not exceed 20 minutes. A suggested approach is to alternate between 20 minutes of heating pad use and 20 minutes of no use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ultrasound therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound therapy is based on the use of ultrasound waves to generate deep heat in order to enhance connective tissue extensibility. The potential benefit of this modality is its ability to improve muscular contracture which increases the joint range of motion. However, despite encouraging data in animal models, the use of ultrasound therapy has led to disappointing results in humans. In one report, for example, exercise coupled with ultrasound therapy for 12 minutes divided into four areas of the knee given two to three times per week over four to six weeks was no better than exercise alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although critics may argue that the optimal dosage, frequency, or interval of treatments is unknown, this study was designed to minimize the ability of these variables to affect the study outcome by utilizing maximal dosages, frequencies, and intervals in terms of patient tolerability. Thus, ultrasound therapy appears to have no proven benefit and is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a therapeutic option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial cooling decreases muscle spasm and increases the threshold of pain [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Cold modalities include ice packs and local spray. Fluoromethane spray, which is nonflammable, is preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14370?source=see_link\">",
"     ethyl chloride",
"    </a>",
"    spray, which is flammable [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/67\">",
"     67",
"    </a>",
"    ]. No studies have addressed the relative merits of cold therapy. Superficial cooling should not be used in patients with the Raynaud phenomenon, cryoglobulinemia, or cold hypersensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data concerning the efficacy of transcutaneous electrical nerve stimulation (TENS) in patients with OA are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A double-blind, randomized, controlled study of 78 patients with knee OA found that daily TENS for four weeks resulted in significant short-term improvement in knee pain, flexion, and duration of morning stiffness [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/68\">",
"       68",
"      </a>",
"      ]. Twenty-four percent of patients using TENS for more than six hours per night had more than a 50 percent improvement in three measured variables (including physician assessment and patient evaluations of pain and function); a similar degree of benefit was seen in only 6 percent of those receiving placebo.",
"     </li>",
"     <li>",
"      A randomized, double-blind, trial compared TENS to placebo in a crossover fashion in patients with symptomatic knee OA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/69\">",
"       69",
"      </a>",
"      ]. The patients receiving TENS experienced more pain relief and had a decreased need for analgesics; however, these benefits occurred only during active use of the device.",
"     </li>",
"     <li>",
"      A double-blind, cross-over trial of 36 patients with knee OA was unable to confirm a positive response to TENS [",
"      <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/70\">",
"       70",
"      </a>",
"      ]. Patients received three weeks of each of three modalities: TENS,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      , and double placebo. No significant difference was noted in pain relief among the three treatment arms. However, a small benefit of TENS might have been masked by a large placebo effect, as 57 percent of patients noted improvement in the double placebo phase. The lack of benefit from TENS may also have reflected the short duration of use prescribed in this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PATIENT EDUCATION AND PSYCHOSOCIAL SUPPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addressing the effect of OA on the patient is a crucial therapeutic concern, as it is in other chronic diseases. Physical limitations, feelings of frustration and dependency, and clinical depression may develop. These elements may reduce the motivation of the patient to comply with aspects of the therapeutic plan including diet, exercise, and medications.",
"   </p>",
"   <p>",
"    The patient evaluation should include an assessment of current coping mechanisms such as activity avoidance and denial. Assessing the patient for symptoms of depression and institution of appropriate counseling and antidepressant therapy when indicated are also important for the treatment of patients with OA. Patient education should include informative, in-depth discussions of the disease and of physical limitations, therapeutic options, and the risks and benefits of the different approaches to management. A summary of information related to the treatment of osteoarthritis that may be useful to patients is provided separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"     \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors have suggested that the impact of psychosocial support may be as substantial as that of medical therapy. As an example, regular reinforcement of management issues with patients by telephone has been associated with decreased joint pain and increased functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. This benefit could occur in patients in whom there was no change in medications and no institution of physical therapy during the period of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5629885\">",
"    <span class=\"h2\">",
"     Self-management programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches that encourage patient self-reliance or self-management commonly rely on principles that are useful in cognitive behavioral therapy. A meta-analysis of 16 trials of self-management for OA of the knee in 2006 concluded that such interventions produced significantly better psychologic outcomes than control interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/33\">",
"     33",
"    </a>",
"    ]. However, improvements in pain and function may depend upon the particular elements of the intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. A variety of strategies, including self-management programs, have been found to improve adherence to exercise and physical activity, but additional trials with long-term follow-up are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/57\">",
"     57",
"    </a>",
"    ]. A telephone-based self-management program that produced moderate improvements in pain in primary care patients with hip or knee OA had two major elements; it provided education related to managing symptoms and helped patients to develop goals and action plans related to OA management [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/74\">",
"     74",
"    </a>",
"    ]. Cognitive behavioral therapy is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41273?source=see_link&amp;anchor=H18#H18\">",
"     \"Psychosocial factors and rheumatic disease\", section on 'Outcomes produced by psychosocial interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other methods that have been tried in the treatment of OA include traditional Chinese medicine, rubifacients (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    ), and mud pack therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Chinese medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proponents of traditional Chinese medicine utilize methods such as herbs, massage, acupuncture, and relaxation techniques for the treatment of OA. While some data supporting these techniques exist [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/76\">",
"     76",
"    </a>",
"    ], the studies are generally uncontrolled. More recent systematic literature reviews and meta-analyses have concluded that acupuncture is slightly better than sham-needling in alleviating pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=see_link\">",
"     \"Acupuncture for rheumatic conditions\"",
"    </a>",
"    .) These techniques can be recommended with reservation for patients with refractory symptoms who desire nontraditional therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Rubifacients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rubifacients and counter irritants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/23/30072?source=see_link\">",
"     topical salicylates",
"    </a>",
"    are frequently used in OA. This probably reflects their ease of use and paucity of adverse effects. The use of these forms of topical therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link&amp;anchor=H34171222#H34171222\">",
"     \"Investigational approaches to the pharmacologic therapy of osteoarthritis\", section on 'Counter-irritants and rubefacients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Mud pack therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mud pack therapy has been used as a treatment modality in several European countries. This therapy has been shown to improve physiologic antioxidant defenses in serum, reduce oxygen radical damage on cartilage, and lower serum levels of prostaglandin E2 and leukotriene B4 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. A study randomly assigned 382 patients with painful knee OA to 18 days of either spa therapy (including mud packs, mineral water baths, knee massage, and supervised group mobilization exercises in a heated mineral water pool) followed by a home exercise program or home exercise alone [",
"    <a class=\"abstract\" href=\"UTD.htm?2/30/2538/abstract/79\">",
"     79",
"    </a>",
"    ]. Usual care (analgesics, NSAIDs, dietary supplements, etc) was allowed in both groups. Spa therapy was associated with a larger proportion of subjects with a minimal or greater clinical response, as defined by a 20 mm or greater decrease from baseline in knee pain when assessed by visual analog scale or 9 or more points on the pain subscale of the WOMAC instrument, six months after the intervention (51 percent versus 36 percent responders, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       \"Patient information: Osteoarthritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"       \"Patient information: Arthritis and exercise (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"       \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8543528\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of osteoarthritis (OA) should be individualized to the patient's expectations, level of function and activity, the joints involved and the severity of the patient's disease, occupational and vocational needs, and any coexisting medical problems. The correct attribution of signs and symptoms at the target site is essential, as pain and other symptoms in a particular area may be referred from OA at other site or may be due to a nonarticular or soft tissue process, such as bursitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pain and other symptoms elicited by prolonged use, resting the affected joint may alleviate pain. Rest is recommended for only short periods of time, typically 12 to 24 hours for acute pain and inflammatory signs, because prolonged rest may lead to muscle atrophy and decreased joint mobility. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rest'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with OA who are overweight, weight loss of even modest degree may produce improvement in lower extremity joint pain and function. Other methods of unloading an osteoarthritic joint include canes and walkers, which can reduce joint forces at the hip by as much as 50 percent. We suggest a trial of soft, elastic heeled sports shoes or the use of insoles for patients with knee OA to diminish impact loading. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Weight loss'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical therapy and orthoses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Braces and splints may be useful for symptomatic relief for those with OA of certain joints. Therapeutic knee taping for pain in the patellofemoral syndrome is controversial, but may be useful for other patients with OA of the knee. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Braces'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Patellofemoral syndrome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Knee taping'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical therapy and exercise improves functional outcome and pain in OA by improving flexibility and by strengthening muscles that support the affected joints. An appropriate exercise program can safely reverse deficiencies in gait, strength, flexibility, aerobic power, and exercise capacity. Compliance with exercise programs varies dramatically according to the regimen selected and the setting, but can be maximized through the use of supervised rather than home exercise programs and other techniques. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical therapy and orthoses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Exercise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Exercise programs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Symptomatic relief'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient compliance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low load effect exercise, warm-up and stretching prior to exercise, and use of splints for joint immobilization can be of benefit for joint protection and reduction in symptoms. Multiple factors should be considered in designing details of exercise regiments for patients with OA, including the pattern of joint involvement, presence or absence of inflammation, muscle condition, range of motion, exercise capacity, and comorbid medical conditions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Joint protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All exercise programs include range of motion and isometric strengthening. For patients with active joint inflammation, advanced disease, or profound functional impairment, these interventions may be the highest level of exercise that can initially be safely achieved. Patients with less severe or more quiescent disease may progress sequentially through isotonic strengthening, aerobic exercises, and, ultimately, to recreational exercise. Low impact exercises to avoid excessive joint loading are preferable for patients with OA. Aquatic exercises are of particular benefit for those with severe arthritis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      marked deconditioning. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Exercise'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Disability prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moist superficial heat can raise the threshold for pain, produce analgesia by acting on free nerve endings, and decrease muscle spasm. Ultrasound therapy appears to have no proven benefit. Superficial cooling decreases muscle spasm and increases the threshold of pain. Data concerning the efficacy of transcutaneous electrical nerve stimulation (TENS) in patients with OA are conflicting. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Heat and cold'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Ultrasound therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Cooling'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'TENS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The psychosocial evaluation should include an assessment of current coping mechanisms, such as activity avoidance and denial, and symptoms of depression. Appropriate counseling and treatment of depression when indicated are also important. Patient education should include informative, in-depth discussions of the disease and of physical limitations, therapeutic options, and the risks and benefits of the different approaches to management. The impact of psychosocial support may be as substantial as that of medical therapy. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Patient education and psychosocial support'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5629885\">",
"       'Self-management programs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/1\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/2\">",
"      Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/3\">",
"      Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/4\">",
"      Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/5\">",
"      Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/6\">",
"      Felson DT, Anderson JJ, Naimark A, et al. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988; 109:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/7\">",
"      Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992; 116:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/8\">",
"      Messier SP, Loeser RF, Miller GD, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum 2004; 50:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/9\">",
"      Fransen M, Crosbie J, Edmonds J. Physical therapy is effective for patients with osteoarthritis of the knee: a randomized controlled clinical trial. J Rheumatol 2001; 28:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/10\">",
"      Radin EL, Yang KH, Riegger C, et al. Relationship between lower limb dynamics and knee joint pain. J Orthop Res 1991; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/11\">",
"      Jones GM, Watt DG. Muscular control of landing from unexpected falls in man. J Physiol 1971; 219:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/12\">",
"      Light LH, McLellan GE, Klenerman L. Skeletal transients on heel strike in normal walking with different footwear. J Biomech 1980; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/13\">",
"      Voloshin A, Wosk J. Influence of artificial shock absorbers on human gait. Clin Orthop Relat Res 1981; :52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/14\">",
"      Yasuda K, Sasaki T. The mechanics of treatment of the osteoarthritic knee with a wedged insole. Clin Orthop Relat Res 1987; :162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/15\">",
"      Sasaki T, Yasuda K. Clinical evaluation of the treatment of osteoarthritic knees using a newly designed wedged insole. Clin Orthop Relat Res 1987; :181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/16\">",
"      Baker K, Goggins J, Xie H, et al. A randomized crossover trial of a wedged insole for treatment of knee osteoarthritis. Arthritis Rheum 2007; 56:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/17\">",
"      Neumann DA. Biomechanical analysis of selected principles of hip joint protection. Arthritis Care Res 1989; 2:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/18\">",
"      Deyle GD, Henderson NE, Matekel RL, et al. Effectiveness of manual physical therapy and exercise in osteoarthritis of the knee. A randomized, controlled trial. Ann Intern Med 2000; 132:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/19\">",
"      Bennell KL, Hinman RS, Metcalf BR, et al. Efficacy of physiotherapy management of knee joint osteoarthritis: a randomised, double blind, placebo controlled trial. Ann Rheum Dis 2005; 64:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/20\">",
"      Hoeksma HL, Dekker J, Ronday HK, et al. Comparison of manual therapy and exercise therapy in osteoarthritis of the hip: a randomized clinical trial. Arthritis Rheum 2004; 51:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/21\">",
"      Chamberlain MA, Care G, Harfield B. Physiotherapy in osteoarthrosis of the knees. A controlled trial of hospital versus home exercises. Int Rehabil Med 1982; 4:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/22\">",
"      Draper ER, Cable JM, Sanchez-Ballester J, et al. Improvement in function after valgus bracing of the knee. An analysis of gait symmetry. J Bone Joint Surg Br 2000; 82:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/23\">",
"      Rannou F, Dimet J, Boutron I, et al. Splint for base-of-thumb osteoarthritis: a randomized trial. Ann Intern Med 2009; 150:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/24\">",
"      Hinman RS, Crossley KM, McConnell J, Bennell KL. Efficacy of knee tape in the management of osteoarthritis of the knee: blinded randomised controlled trial. BMJ 2003; 327:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/25\">",
"      Messier SP, Loeser RF, Hoover JL, et al. Osteoarthritis of the knee: effects on gait, strength, and flexibility. Arch Phys Med Rehabil 1992; 73:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/26\">",
"      Philbin EF, Groff GD, Ries MD, Miller TE. Cardiovascular fitness and health in patients with end-stage osteoarthritis. Arthritis Rheum 1995; 38:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/27\">",
"      Fisher NM, Pendergast DR. Effects of a muscle exercise program on exercise capacity in subjects with osteoarthritis. Arch Phys Med Rehabil 1994; 75:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/28\">",
"      Minor MA, Hewett JE, Webel RR, et al. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1989; 32:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/29\">",
"      Talbot LA, Gaines JM, Ling SM, Metter EJ. A home-based protocol of electrical muscle stimulation for quadriceps muscle strength in older adults with osteoarthritis of the knee. J Rheumatol 2003; 30:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/30\">",
"      Kovar PA, Allegrante JP, MacKenzie CR, et al. Supervised fitness walking in patients with osteoarthritis of the knee. A randomized, controlled trial. Ann Intern Med 1992; 116:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/31\">",
"      Ettinger WH Jr, Burns R, Messier SP, et al. A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST). JAMA 1997; 277:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/32\">",
"      van Baar ME, Assendelft WJ, Dekker J, et al. Effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a systematic review of randomized clinical trials. Arthritis Rheum 1999; 42:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/33\">",
"      Devos-Comby L, Cronan T, Roesch SC. Do exercise and self-management interventions benefit patients with osteoarthritis of the knee? A metaanalytic review. J Rheumatol 2006; 33:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/34\">",
"      Fransen M, McConnell S. Land-based exercise for osteoarthritis of the knee: a metaanalysis of randomized controlled trials. J Rheumatol 2009; 36:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/35\">",
"      American Geriatrics Society Panel on Exercise and Osteoarthritis. Exercise prescription for older adults with osteoarthritis pain: consensus practice recommendations. A supplement to the AGS Clinical Practice Guidelines on the management of chronic pain in older adults. J Am Geriatr Soc 2001; 49:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/36\">",
"      Thorstensson CA, Roos EM, Petersson IF, Ekdahl C. Six-week high-intensity exercise program for middle-aged patients with knee osteoarthritis: a randomized controlled trial [ISRCTN20244858]. BMC Musculoskelet Disord 2005; 6:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/37\">",
"      Minor MA. Exercise in the management of osteoarthritis of the knee and hip. Arthritis Care Res 1994; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/38\">",
"      Judge JO, Underwood M, Gennosa T. Exercise to improve gait velocity in older persons. Arch Phys Med Rehabil 1993; 74:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/39\">",
"      Thomas KS, Muir KR, Doherty M, et al. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. BMJ 2002; 325:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/40\">",
"      Baker KR, Nelson ME, Felson DT, et al. The efficacy of home based progressive strength training in older adults with knee osteoarthritis: a randomized controlled trial. J Rheumatol 2001; 28:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/41\">",
"      Song R, Lee EO, Lam P, Bae SC. Effects of tai chi exercise on pain, balance, muscle strength, and perceived difficulties in physical functioning in older women with osteoarthritis: a randomized clinical trial. J Rheumatol 2003; 30:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/42\">",
"      Wang C, Schmid CH, Hibberd PL, et al. Tai Chi is effective in treating knee osteoarthritis: a randomized controlled trial. Arthritis Rheum 2009; 61:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/43\">",
"      Doucette SA, Goble EM. The effect of exercise on patellar tracking in lateral patellar compression syndrome. Am J Sports Med 1992; 20:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/44\">",
"      Schnitzer TJ, Popovich JM, Andersson GB, Andriacchi TP. Effect of piroxicam on gait in patients with osteoarthritis of the knee. Arthritis Rheum 1993; 36:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/45\">",
"      Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, et al. Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 1989; 262:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/46\">",
"      Blair SN, Kohl HW, Gordon NF, Paffenbarger RS Jr. How much physical activity is good for health? Annu Rev Public Health 1992; 13:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/47\">",
"      Fielding RA. The role of progressive resistance training and nutrition in the preservation of lean body mass in the elderly. J Am Coll Nutr 1995; 14:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/48\">",
"      Prior JC, Barr SI, Chow R, Faulkner RA. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 5. Physical activity as therapy for osteoporosis. CMAJ 1996; 155:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/49\">",
"      Smith EL, Gilligan C. Dose-response relationship between physical loading and mechanical competence of bone. Bone 1996; 18:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/50\">",
"      Physical activity and cardiovascular health. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. JAMA 1996; 276:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/51\">",
"      Biddle S. Exercise and psychosocial health. Res Q Exerc Sport 1995; 66:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/52\">",
"      Hoffman DF. Arthritis and exercise. Prim Care 1993; 20:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/53\">",
"      Hicks JE. Exercise in patients with inflammatory arthritis and connective tissue disease. Rheum Dis Clin North Am 1990; 16:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/54\">",
"      Yack HJ, Collins CE, Whieldon TJ. Comparison of closed and open kinetic chain exercise in the anterior cruciate ligament-deficient knee. Am J Sports Med 1993; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/55\">",
"      Bynum EB, Barrack RL, Alexander AH. Open versus closed chain kinetic exercises after anterior cruciate ligament reconstruction. A prospective randomized study. Am J Sports Med 1995; 23:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/56\">",
"      McNeal RL. Aquatic therapy for patients with rheumatic disease. Rheum Dis Clin North Am 1990; 16:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/57\">",
"      Jordan JL, Holden MA, Mason EE, Foster NE. Interventions to improve adherence to exercise for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev 2010; :CD005956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/58\">",
"      Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis 2005; 64:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/59\">",
"      McAlindon TE, Jacques P, Zhang Y, et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis? Arthritis Rheum 1996; 39:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/60\">",
"      McAlindon TE, Felson DT, Zhang Y, et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996; 125:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/61\">",
"      Brand C, Snaddon J, Bailey M, Cicuttini F. Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomised, placebo controlled study. Ann Rheum Dis 2001; 60:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/62\">",
"      HOLLANDER JL, HORVATH SM. The influence of physical therapy procedures on the intra-articular temperature of normal and arthritic subjects. Am J Med Sci 1949; 218:543.",
"     </a>",
"    </li>",
"    <li>",
"     Fischer E, Solomon S. Physiological responses to heat and cold. In: Therapeutic Heat and Cold, Licht S (Ed), E Licht, New Haven, CT 1965. p.126.",
"    </li>",
"    <li>",
"     Hicks JE, Gerber LH. Rehabilitation in the management of patients with osteoarthritis. In: Osteoarthritis: Diagnosis and Medical/Surgical Management, Moskowitz RW, Howell DS, Goldberg VM, Mankin HJ (Eds), WB Saunders, Philadelphia 1992. p.433.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/65\">",
"      Falconer J, Hayes KW, Chang RW. Effect of ultrasound on mobility in osteoarthritis of the knee. A randomized clinical trial. Arthritis Care Res 1992; 5:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/66\">",
"      Benson TB, Copp EP. The effects of therapeutic forms of heat and ice on the pain threshold of the normal shoulder. Rheumatol Rehabil 1974; 13:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/67\">",
"      Mennell J. Spray-stretch for the relief of pain from muscle spasm and myofascial trigger points. J Am Podiatry Assoc 1976; 66:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/68\">",
"      Zizic TM, Hoffman KC, Holt PA, et al. The treatment of osteoarthritis of the knee with pulsed electrical stimulation. J Rheumatol 1995; 22:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/69\">",
"      Taylor P, Hallett M, Flaherty L. Treatment of osteoarthritis of the knee with transcutaneous electrical nerve stimulation. Pain 1981; 11:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/70\">",
"      Lewis B, Lewis D, Cumming G. The comparative analgesic efficacy of transcutaneous electrical nerve stimulation and a non-steroidal anti-inflammatory drug for painful osteoarthritis. Br J Rheumatol 1994; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/71\">",
"      Ren&eacute; J, Weinberger M, Mazzuca SA, et al. Reduction of joint pain in patients with knee osteoarthritis who have received monthly telephone calls from lay personnel and whose medical treatment regimens have remained stable. Arthritis Rheum 1992; 35:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/72\">",
"      Weinberger M, Hiner SL, Tierney WM. Improving functional status in arthritis: the effect of social support. Soc Sci Med 1986; 23:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/73\">",
"      Weinberger M, Tierney WM, Booher P, Katz BP. Can the provision of information to patients with osteoarthritis improve functional status? A randomized, controlled trial. Arthritis Rheum 1989; 32:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/74\">",
"      Allen KD, Oddone EZ, Coffman CJ, et al. Telephone-based self-management of osteoarthritis: A randomized trial. Ann Intern Med 2010; 153:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/75\">",
"      Buszewicz M, Rait G, Griffin M, et al. Self management of arthritis in primary care: randomised controlled trial. BMJ 2006; 333:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/76\">",
"      Chen W, Li Z, Zhang J. Treating osteoarthritis of the knee joint by traditional Chinese medicine. J Tradit Chin Med 1994; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/77\">",
"      Bellometti S, Cecchettin M, Galzigna L. Serum antioxidant modifications in osteoarthritic patients after mud-pack. Bioch Clin 1995; 7-8:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/78\">",
"      Bellometti S, Galzigna L. Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 1998; 46:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/30/2538/abstract/79\">",
"      Forestier R, Desfour H, Tessier JM, et al. Spa therapy in the treatment of knee osteoarthritis: a large randomised multicentre trial. Ann Rheum Dis 2010; 69:660.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5494 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-46D95CF9A3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2538=[""].join("\n");
var outline_f2_30_2538=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8543528\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      WEIGHT LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHYSICAL THERAPY AND ORTHOSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Braces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patellofemoral syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Knee taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Symptomatic relief",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Joint protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Disability prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aerobic versus resistance (strengthening) exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unanswered questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HEAT AND COLD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ultrasound therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cooling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PATIENT EDUCATION AND PSYCHOSOCIAL SUPPORT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5629885\">",
"      Self-management programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Chinese medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Rubifacients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Mud pack therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8543528\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5494|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/25/26015\" title=\"algorithm 1\">",
"      Treatment of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7607?source=related_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32407?source=related_link\">",
"      Joint protection program for the lower limb",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43993?source=related_link\">",
"      Patellofemoral pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=related_link\">",
"      Patient guidelines for weight-resistance training in osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=related_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/19/41273?source=related_link\">",
"      Psychosocial factors and rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=related_link\">",
"      Weight-resistance training in patients with osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_30_2539="Risk factors syphilis pregnancy";
var content_f2_30_2539=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50671&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors associated with syphilis in pregnancy in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Poverty",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexual promiscuity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sex worker",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Use of illicit drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human immunodeficiency virus infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lack of regular prenatal care",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age 25 to 29 years",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hispanic ethnicity or African-American race",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uninsured",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2539=[""].join("\n");
var outline_f2_30_2539=null;
var title_f2_30_2540="Blood pressure children";
var content_f2_30_2540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal blood pressure in children: 50th to 90th percentiles",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Systolic pressure, mm Hg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic pressure, mm Hg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth, 12 hr, &lt;1000g",
"       </td>",
"       <td>",
"        39-59",
"       </td>",
"       <td>",
"        16-36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth, 12 hr, 3 kg",
"       </td>",
"       <td>",
"        50-70",
"       </td>",
"       <td>",
"        25-45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonate, 96 hr",
"       </td>",
"       <td>",
"        60-90",
"       </td>",
"       <td>",
"        20-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant, 6 mo",
"       </td>",
"       <td>",
"        87-105",
"       </td>",
"       <td>",
"        53-66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toddler, 2 yr",
"       </td>",
"       <td>",
"        95-105",
"       </td>",
"       <td>",
"        53-66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        School age, 7 yr",
"       </td>",
"       <td>",
"        97-112",
"       </td>",
"       <td>",
"        57-71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adolescent, 15 yr",
"       </td>",
"       <td>",
"        112-128",
"       </td>",
"       <td>",
"        66-88",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The median (50th percentile) systolic blood pressure for children older than 1 year may be approximated by the following formula: 90 mm Hg + (2 x age in years). The lower limit (5th percentile) of systolic blood pressure can be estimated with this formula: 70mm Hg + (2 x age in years).",
"    <br>",
"     A low systolic blood pressure should prompt an immediate evaluation for additional signs of inadequate perfusion, such as diminished mental status, prolonged capillary refill, and tachycardia.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Data from: Vershold, H. Aortic blood pressure during the first 12 hours of life in infants with birth weight 610-4220 grms. Pediatrics 1981; 67:107 and Report of the second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 1987; 79:1.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2540=[""].join("\n");
var outline_f2_30_2540=null;
var title_f2_30_2541="10th percentile by gestational age and sex";
var content_f2_30_2541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tenth percentile of birth weight (g) for gestational age by gender: United States, 1991, single live births to resident mothers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Male",
"       </td>",
"       <td class=\"subtitle1\">",
"        Female",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        256",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        328",
"       </td>",
"       <td>",
"        310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        388",
"       </td>",
"       <td>",
"        368",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        446",
"       </td>",
"       <td>",
"        426",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        504",
"       </td>",
"       <td>",
"        480",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        570",
"       </td>",
"       <td>",
"        535",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        644",
"       </td>",
"       <td>",
"        592",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        728",
"       </td>",
"       <td>",
"        662",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        828",
"       </td>",
"       <td>",
"        760",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        956",
"       </td>",
"       <td>",
"        889",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        1117",
"       </td>",
"       <td>",
"        1047",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        1308",
"       </td>",
"       <td>",
"        1234",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        1521",
"       </td>",
"       <td>",
"        1447",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        1751",
"       </td>",
"       <td>",
"        1675",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        1985",
"       </td>",
"       <td>",
"        1901",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        2205",
"       </td>",
"       <td>",
"        2109",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        2407",
"       </td>",
"       <td>",
"        2300",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        2596",
"       </td>",
"       <td>",
"        2484",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        2769",
"       </td>",
"       <td>",
"        2657",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2908",
"       </td>",
"       <td>",
"        2796",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        2986",
"       </td>",
"       <td>",
"        2872",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        3007",
"       </td>",
"       <td>",
"        2891",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        2998",
"       </td>",
"       <td>",
"        2884",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        2977",
"       </td>",
"       <td>",
"        2868",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        2963",
"       </td>",
"       <td>",
"        2853",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Obstetricians and Gynecologists (Obstetrics and Gynecology, 1996; 87:163).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2541=[""].join("\n");
var outline_f2_30_2541=null;
var title_f2_30_2542="Contents: Nephrology calculators";
var content_f2_30_2542=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Nephrology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Nephrology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16513\">",
"           Calculator: Creatinine clearance (measured)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30609\">",
"           Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19809\">",
"           Calculator: Creatinine clearance estimate by Cockcroft-Gault equation (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/50/7970\">",
"           Calculator: Fractional excretion of magnesium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/59/18354\">",
"           Calculator: Fractional excretion of magnesium (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/13/25809\">",
"           Calculator: Fractional excretion of sodium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/28/25025\">",
"           Calculator: Fractional excretion of sodium (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/53/27473\">",
"           Calculator: Glomerular filtration rate estimate by CKD-EPI equation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10194\">",
"           Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35745\">",
"           Calculator: Kt/V Dialysis Dose Daugirdas Formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/17/4370\">",
"           Calculator: Residual Renal Function in Hemodialysis Patients (Kru)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1298\">",
"           Calculator: Serum anion gap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/45/28370\">",
"           Calculator: Serum osmolal gap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20786\">",
"           Calculator: Serum osmolal gap (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16673\">",
"           Calculator: Urinary protein excretion estimation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/8/6273\">",
"           Calculator: Urine anion gap",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-9A08797CE0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_30_2542=[""].join("\n");
var outline_f2_30_2542=null;
var title_f2_30_2543="CT choanal atresia";
var content_f2_30_2543=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT image of choanal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial computed tomography (CT) image of choanal atresia. Note the bony narrowing of the posterior nose.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_30_2543=[""].join("\n");
var outline_f2_30_2543=null;
